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ABSTRACT
Microglial cells are immune cells that protect the central nervous system and are subject to HIV1 infection. HIV-1 infection of these cells can lead to HIV Associated Neurocognitive Disorders
(HAND). Since HIV-1 only codes for 15 different proteins, the virus also uses cellular factors,
like Cyclophilin A (CypA), to assist in viral replication. The cell also has antiretroviral
restriction factors, like tripartite motif-containing protein 5 (TRIM5α), to protect against
infection. The goal of this project is to investigate the role of CypA in the early steps of HIV-1
replication and TRIM5α restriction in microglial cells. I hypothesize that CypA facilitates HIV-1
infection and assists in normal capsid uncoating kinetics. I also predict that blocking CypA
interaction will allow for TRIM5α restriction to decrease HIV-1 infection. To study how the
interaction between CypA and the capsid affects uncoating, the in situ uncoating assay was
performed in the presence and absence of the drug Cyclosporin A which blocks this interaction.
Lower amounts of CA were found in conditions with CypA binding compared to the absence of
CypA. This result suggests that CypA assists with uncoating in CHME3 cells. To research the
interplay between CypA and TRIM5α in microglial cells, TRIM5α expression was knocked
down using siRNAs and CsA treatment was used to block CypA binding to the capsid. A
decrease in TRIM5α expression resulted in an increase of HIV-1 infectivity. This effect was
greater when CypA interactions were inhibited. This data indicates that TRIM5α restriction
occurs in CHME3 microglial cells when CypA is inhibited. It is likely that CypA plays more
than one role in HIV-1 infectivity and replication. Here, I have characterized the effect of CypA
on HIV-1 uncoating and the connection between CypA and TRIM5α in microglial cells.
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INTRODUCTION

Human immunodeficiency virus (HIV) infection causes acquired immunodeficiency
syndrome (AIDS). HIV has two main groups: HIV-1 and HIV-2 and within these groups there
are more than ten different strains. For HIV-1, M is the most common strain, making up close to
90% of infected individuals (1). HIV-1 can only infect and replicate in cells that have the cluster
of differentiation 4 (CD4) receptor, and a majority of these cells are involved in the immune
system (2). Viral infection of CD4+ T cells damages immunity and leads to the onset of AIDS
(2). Once the immune system is critically damaged, the body is susceptible to opportunistic
infections (2). For HIV infection and replication to occur, virions use both viral and cellular
factors. Throughout early and late replication, HIV-1 commandeers cellular proteins, such as
cyclophilin A (CypA), to aid in the infection process. There are also cellular factors, like
tripartite motif-containing protein 5 (TRIM5α) that restrict viral infection. The goal of this
project is to investigate the effect of CypA on HIV-1 capsid uncoating kinetics and the
relationship between TRIM5α and CypA in relation to HIV-1 infection and uncoating.
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LITERATURE REVIEW

HIV-1 Associated Neurocognitive Disorders and Microglia
HIV is transmitted through bodily fluids. This includes direct blood to blood contact,
seminal, anal, and vaginal fluids, and breast milk (3). Common modes of transmission include
unprotected sex, sharing needles, and transmission from mother to child. HIV cannot be
transmitted by shaking hands, coughing, or other everyday interactions (3). As infection takes
hold throughout the body, the infected individual’s immune system is extremely damaged. Once
HIV infection has reached the most severe stage, stage 3, it is classified as AIDS (4). This leaves
the body susceptible to opportunistic infections. The conditions associated with AIDS come in a
wide range and include a variety of cancers, tuberculosis, pneumonia, and neurocognitive
disorders (4).
As infected individuals are able to live longer lifespans, they discover the long-term
effects of HIV-1 infection. Neural immune cells contain the CD4 receptor and are susceptible to
HIV-1 infection. To access the brain, HIV must cross the blood brain barrier (BBB). This barrier
protects the brain from pathogens and toxins circulating in the blood (5). HIV can migrate across
the BBB inside infected cells and as free virus (6). HIV-1 can infect the epithelial cells of the
brain and the choroid plexus that make up the BBB. The virus can also infect macrophages
locate in the central nervous system (CNS). Macrophages in the CNS are also called microglial
cells (6). Infected, inactivated microglial cells form a viral reservoir stored in the CNS and the
reservoir does not produce virus until the cells are activated (6). As for migration of free virus
across the BBB, the exact mechanism for transport remains heavily investigated (6).
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Once HIV-1 infects the brain, an individual may develop HIV-1 associated
neurocognitive diseases (HAND). There are three subcategories under HAND; asymptomatic
neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated
dementia (HAD). Increasing with each disorder respectively, the individual’s neurocognitive
impairment interferes with their daily life (7). The qualitative impairment tends to fluctuate from
day to day, similar to elderly cognitive impairment (8). Of the HIV positive community, anyone
infected with the virus, 20% to 50% are estimated to develop HAND (7). Treatments focus on
decreasing the viral load in the brain. Combination antiretroviral treatment (cART) can
successfully lower viral counts in the parenchyma and the cerebrospinal fluid (7). Though HIV
cannot be fully removed from the body, cART can decrease the effects of infection.
A major barrier in treating HIV-1 infection is the viral reservoir. The reservoir is a group
of inactive CD4+ memory immune cells that become infected (9). The cells are extremely
difficult to target because they lack any distinct difference from uninfected cells. When the
inactive memory cells activate, they begin producing virus and greatly contribute to increasing
total viral load (9). Within the central nervous system, microglial cells create a viral reservoir.
These cells contribute to the immune defense in the brain and contain the CD4 receptor. They
both protect from pathogens and protect injured portions of the brain (10). As most HIV research
focuses on T-cells, the specifics of HIV-1 infection in microglial cells continues to be
investigated.

HIV-1 Structure
HIV is an enveloped virus that measures about 100 nm in diameter (11). The exterior is
made up of a lipid bilayer with imbedded viral proteins (Fig. 1). These proteins are primarily
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envelope glycoprotein 120 (gp120) and envelope glycoprotein 41 (gp41). The proteins within the
outer membrane assist with anchoring and infection (11). The lipid bilayer is derived from the
host cell that produced the virion (12). Underneath the membrane is a matrix shell made up of
the HIV matrix protein (MA) that lines the inside of the virion (12). Within the matrix shell is the
conical capsid made of capsid protein (CA). The capsid holds the viral genetic material and
accessory proteins (12). The accessory proteins include nucleocapsid protein (NC), protease,
reverse transcriptase, integrase, Nef, Vif, and Vpr ((12); Fig. 1). The complex structure and
contents of the virus allow it to effectively infect cells and replicate.

HIV-1 Replication
Infection begins with fusion of a virion to the cell membrane (Fig. 2). Bringing the two
membranes together is not kinetically favorable due to hydration repulsion. Therefore, for this
action to occur, viral fusion proteins must change from a high energy to low energy
conformation. For entry, HIV-1 gp120 binds to the CD4 receptor found on the extracellular
membrane. Interaction between gp120 and the receptor causes a conformational change in gp120
allowing interaction with a CC chemokine receptor 5 (CCR5) coreceptor. For infection to occur,
both CD4 and CCR5 must be present on the cell surface. Interaction with CCR5 triggers gp41,
an N terminal fusion peptide, to interact with the cell membrane (14, 15). Once gp41 reaches this
stage, it triggers a cascade of events to draw the two membranes together. Gp41 has the C
terminal end in the viral membrane and the N terminal end in the cellular membrane. The gp41
protein rearranges and refolds to form a hairpin, making a six-helix bundle (16). This bundle,
called the postfusion conformation, puts the C terminal and N terminal ends of gp41 next to each
other to draw the membranes together. Partial fusion begins with the formation of a
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hemifusion stalk followed by a fusion pore. Then, the two membranes become one to complete
fusion and deposit the viral capsid into the cell (16).
Once the capsid enters the cell, a series of cytoplasmic events occur. The exact order of
each event remains to be determined. A necessary step for HIV replication is reverse
transcription (Fig. 2). During reverse transcription the viral RNA is reverse transcribed to viral
complementary DNA (cDNA). For reverse transcription to occur, the reverse transcription
complex (RTC) must form. The RTC is made up of nucleocapsid protein, viral accessory
proteins, reverse transcriptase, and integrase (17). This process begins with binding of a tRNA
primer near the 5’ end of the RNA template (18). Next, the RTC reverse transcribes singlestranded RNA into double-stranded DNA through a series of elongation and strand switching
steps (19). The RTC degrades the RNA template as it completes reverse transcription, so
switching strands from the minus DNA strand to the plus DNA strand is necessary for the
complex to continue using a template (19). As reverse transcription occurs, the virus travels
towards the nucleus using the cytoskeleton (13). At an undetermined part of replication, the RTC
becomes a preintegration complex (PIC) in preparation for nuclear entry (20).
Many specifics about HIV-1 nuclear entry have yet to be defined and because of this,
there are multiple models of nuclear import. A major difference between the models focuses on
whether or not the capsid has uncoated. Uncoating is when CA disassociates from the conical
capsid. In theory, if the capsid uncoats in the cytoplasm, viral PICs are expected to enter the
nucleus with little resistance (21, 22). If the capsid remains intact and uncoats at the nuclear
pore, it will take longer for viral entry because of the bulky capsid. In reality, viral nuclear entry
may occur in a combination of these two possible models (23). Once nuclear entry is complete,
integration begins. Integration is the process of inserting viral cDNA into the host cell genome.
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This process, catalyzed by the viral enzyme integrase, begins with the removal of two
nucleotides from the 3’ end of viral cDNA. Exposed 3’ ends attack host DNA at targeted sites,
joining the 3’ end of viral cDNA to the 5’ end of host DNA (24). Next, nucleotides are removed
from the 5’ end of viral cDNA, so it may join the 3’ end of host DNA (24). Viral genetic material
is now inserted into the host genome, forming a provirus.
Using cellular proteins, the integrated cDNA is transcribed and translated (Fig. 2). HIV
genomes are made up of gag, pol, env, and accessory genes (25). Within integrated viral DNA,
there is an enhancer sequence upstream from transcription factor binding sites (26). This
enhancer, known as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB),
increases expression of the viral accessory protein Tat. Tat interacts with a trans-activation
response element to increase the number of full-length viral mRNA transcribed. Tat also forms a
positive feedback loop with NF-κB to increase viral transcription and effectively acts as an
activator for viral transcripts (26). Viral transcripts undergo RNA editing by cellular factors,
such as adenosine deaminases acting on RNA 1 (ADAR1). Editing must occur for proper
formation of the p24 viral protein (27). During translation, HIV-1 hijacks the necessary
machinery, including ribosomes, tRNAs, and mRNA binding proteins (28). Rev, a viral protein,
is an integral part of this process because it recognizes and binds to Rev responsive elements
(RRE) on viral transcripts (29). Rev binds to HIV mRNA to increase stability and assist with
nuclear export into the cytoplasm. Translation initiation factors can recognize Rev bound RRE
and begin assembling the polysome. Without Rev, viral mRNA is unrecognizable, and this lack
of recognition is detrimental for HIV replication (29).
Viral proteins and untranslated viral RNA assemble on the intracellular membrane. Gag,
a structural protein, is the first to reach the membrane and targets lipid rafts. The remaining viral
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proteins follow gag to assemble at the intracellular side of the membrane (31). Gag recruits
endosomal sorting complexes required for transport (ESCRT) to the site. ESCRT catalyzes
membrane fission and finalizes the budding step of HIV-1 replication (31). However, the
released virion is not yet mature, until a viral protease enzyme cleaves the polyprotein GagPol.
Protease cleaves gag into four distinct factors: matrix protein (MA), capsid protein (CA),
nucleocapsid protein (NC), and p6 protein (Fig. 2). NC and MA are associated directly with the
membrane and CA forms the capsid (Fig. 1; (31)). At this point, mature virions can infect more
CD4+ host cells.

The HIV-1 Capsid
The HIV-1 capsid is formed during virion maturation when CA assembles to form the
conical core of the virus. A complete capsid is made up of approximately 1,500 CA (Fig. 3;
(32)). The CA itself is comprised of two main domains: N-terminal domain (CANTD) and Cterminal domain (CACTD). CANTD consists of seven alpha helices known as H1 through H7.
Similarly, CACTD is made up of four alpha helices labeled H8 through H11 (33). Both domains
are connected by a linker and together they associate around a central ring to form hexamers and
pentamers (34). The hexamers and pentamers then bind together to form a fullerene cone that is
capped on both ends. The flexible lattice presents itself as two types of curved surfaces located in
the body and ends of the cone. The curves on the capsid ends are structured as twelve pentameric
declinations and the body is made up of hexameric lattice curvatures (35).
HIV-1 capsid houses genomic RNA, NC, reverse transcriptase, and other miscellaneous
viral components (32). One of the key functions the capsid performs is protecting its contents
from detection and degradation. For example, HIV-1 cDNA is susceptible to the DNA sensor
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cyclic GMP-AMP sensor (cGAS), yet this sensor does not detect viral cDNA as it travels
towards the nucleus within the capsid (36). Similarly, during infection, HIV-1 recruits cleavage
and polyadenylation specificity factor subunit 6 (CPSF6) seemingly to protect against DNA
sensors and protection against triggering an innate immune response (37). The capsid also
functions to assist with the infection process through uncoating kinetics. There have been links to
uncoating discovered in reverse transcription, nuclear pore complex recognition, and DNA
integration. Studies have found that treatment with the reverse transcription inhibitor nevirapine
delayed core uncoating (38). Another study found that CA was necessary for nuclear import,
meaning that CA must be present in some form during import (39). It was also found that
different capsid mutants integrated at different sites, linking CA to integration (40). Though the
exact timing of capsid uncoating remains unknown, the process is intrinsically linked with
infection and overall proper uncoating kinetics are crucial for HIV-1 infectivity.

Models of HIV-1 Capsid Uncoating
Regardless of how much is known about the HIV-1 conical capsid, the exact process of
uncoating remains a mystery. Because of this, many models are suggested. The first model, rapid
core disassembly, suggests CA monomers disassemble directly upon cytoplasmic entry (Fig.
4A). As the capsid immediately releases its contents into the cell, reverse transcription occurs
freely within the cytoplasm (13). Evidence for this version of uncoating was based around an
experiment that found very little CA and NC present post integration, but both MA and RT were
within the cytoplasm (41). Support for this version of uncoating lasted for many years (13). As
research on capsid uncoating progressed, rapid core disassembly was disputed. Studies have
shown that isolated RTCs, analyzed directly after infection, contain CA (13). Similarly, the
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interaction between cellular factors and CA disproves this version of capsid disassembly (42). If
the core uncoated immediately upon entry, then cellular factors would not have ample time to
bind to CA. It is also known that certain cellular antiretroviral proteins, such as TRIM5α bind to
the capsid and disrupt uncoating. This process occurs in the cytoplasm, again contradicting
immediate uncoating (43). Though evidence suggests that capsid uncoating does not happen
immediately, there are many other viable models for this process.
As the capsid travels towards the nucleus, it is possible that uncoating occurs in the
cytosol. Therefore, the next model is biphasic, or cytoplasmic, uncoating, where CA dissociate in
the cytoplasm while the capsid is traveling to the nucleus (Fig. 4B). Simultaneously, as CA
detaches, RNA undergoes reverse transcription (13). This model is supported by studies using
a cyclosporin (CsA) washout assay and an immunofluorescent assay (38). The CsA washout
assay measures capsid uncoating kinetics using TRIM-CypA, a restriction factor found in owl
monkey kidney (OMK) cells. The half-life of uncoating, about one hour post infection,
corresponds with production of early reverse transcription products (38). An immunofluorescent
assay revealed a similar outcome within HeLa cells. The fluorescent signal associated with CA
significantly decreased by one hour post infection. This suggests that CA begin uncoating within
the cytoplasm and release the RTC while traveling towards the nucleus (44). However, if capsid
uncoating occurs early in the infection process, then the capsid’s function to protect the contents
within from host cell antiretroviral attacks may not be possible, leaving viral RNA and RTC
susceptible to host cell restriction factors and DNA sensors. If the capsid’s intended function is
to protect the contents within from host cell antiretroviral attacks, then this protection may not be
possible if CA dissociation begins early within the infection process (13). Though there is
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evidence that uncoating begins in the cytoplasm, it may not be where a majority of uncoating
occurs.
Another model for uncoating is nuclear pore complex (NPC) uncoating where CA
disassembly occurs during nuclear entry (Fig. 4C). Here, reverse transcription is modeled to
happen while entirely encompassed by the capsid (13). Support for this model comes from the
antiretroviral DNA sensor, cGAS. HIV-1 viral cDNA is susceptible to cGAS sensors but can
escape when within the capsid. In dendritic cells, cGAS does not recognize cytoplasmic HIV
cDNA as it is being transcribed, suggesting that the capsid stays intact to protect cDNA from
host cell DNA sensors by staying intact until it reaches the NPC (36). Using cryogenic scanning
electron microscopy (cryo SEM), intact conical viral cores were imaged in proximity to nuclear
pores. As the capsids remained in their original structure near NPCs, a major uncoating event
may not happen until nuclear entry (45). The intact cores were imaged up to 48 hours post
infection. However, previous data displays that capsid uncoating, reverse transcription, and
nuclear localization is entirely complete by that time (13). Therefore, this model does not support
the intrinsic link between uncoating and reverse transcription. Due to the contrasting data on
uncoating, it is possible that this process varies in differing cell types, or environments.
The most recently proposed model of capsid dissociation is nuclear uncoating. In this
process, the capsid remains intact until after nuclear import. The capsid fully disassociates once
within the nucleus (Fig. 5; (46)). Verification for this model came from using a GFP tagged CA
and live cell microscopy in HeLa, CEM-ss cells and macrophages. Intact or nearly intact viral
cores were imaged within the nucleus 1.5 hours post infection (39). Further support for nuclear
uncoating used a destabilizing compound, PF74. When the capsid was exposed to PF74 within
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the nucleus, CA remained susceptible, meaning that the conical core remained intact within the
nucleus. PF74 destabilizes the bonds between CA and therefore only works on intact capsid.
Presence of intact capsid within the nucleus was observed in THP1 macrophages, MDM
cells, Sup T1 T-cells, and CD4+ T-cells. Similarly, when NPC inhibitors were administered to
the cells, intact capsid could still be located within the nucleus. It was concluded that it is
entirely possible that HIV-1 uses multiple NPC import pathways to access the nucleus (47). As
this model becomes predominant within the field of HIV-1 uncoating research, it remains
probable that this process occurs in many forms and may differ between cell types.

Viral Factors That Effect Uncoating
To assist in uncoating, there are interactions inside and outside of the capsid. Many
studies have found viral factors that affect the capsid. For example, HIV-1 integrase (IN) is a
protein responsible for integrating viral cDNA into host cell DNA, yet this is not its only
purpose. IN has been found to directly affect capsid uncoating by adding stability to the CA
hexamers and pentamers (48). Absence of IN, or mutations in IN, decreased total capsid as well
as slowed the rate of CA disassembly. One study concluded that IN assists CA interaction with
cellular factors involved in the infection process, such as CypA (48). Another viral factor
involved in capsid uncoating is reverse transcriptase. Inhibiting reverse transcription with
nevirapine caused a delay in capsid uncoating (38, 49, 50). This finding lends to the possibility
of stable DNA-RNA hybrids or double stranded DNA, made by reverse transcriptase, placing
stress on the inside of the capsid. This coincides with the theory that the products made during
reverse transcription may assist with capsid uncoating. Similarly, mutated capsid cores that
increase stability do exhibit defective reverse transcription (13). This goes along with the thought
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that core remodeling must happen to accommodate the transition from flexible RNA to ridged
double stranded DNA (13). The viral factors involved with HIV-1 uncoating appear to greatly
assist in the overall process.

Cellular Factors That Interact With HIV-1
Due to the small number of proteins within HIV-1 virions, the virus has adapted to using
cellular factors to assist in infection. CPFS6 interacts directly with CA and assists with viral
cDNA integration. Without CPFS6-CA interactions, the PIC is not properly positioned within the
nucleus (51). Transportin-SR2 (TNPO3) is a protein that assists in the nuclear import of
serine/arginine splicing factors. TNPO3 interacts with IN and therefore assists in PIC nuclear
import. In addition, TNPO3 binds to CA and may destabilize the capsid to assist in uncoating. It
is also possible TNPO3 interacting with CA facilitates CPFS6-CA interactions (52, 53). Other
cellular proteins that interact with HIV-1 capsids are nuclear pore complex proteins, including
Nup358 and Nup153. Nup358 has a domain similar to CypA and promotes CA isomerization
that may assist with uncoating. Knocking down Nup153 decreases 2-LTR circles. 2-LTR circles
are unintegrated viral DNA that contain two long term repeat sequences. These stretches of DNA
can be amplified by PCR and are used to mark nuclear import as they only occur in the nucleus
(54). Since decreasing expression of Nup153 decreased nuclear import marker, it is concluded
that this protein is necessary for effective nuclear import (13). Similarly, CypA interacts directly
with the CA. This protein binds specifically to a CypA binding loop on CA and has a variety of
effects on capsid uncoating kinetics.
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Cyclophilin A
CypA is a cellular protein classified as a peptidyl prolyl isomerase (PPIase). It is made up
of 165 amino acids with a weight of 17 kDa (55). Proteins classified as PPIase assist in protein
folding catalyzation by altering proline residues between cis and trans configurations (56). An
interaction between CypA and HIV-1 was discovered many years ago, but the results of this
interaction remain unspecified. The CA domain of viral Gag binds to a hydrophobic pocket on
the surface of CypA (42). Interestingly, the cell is depleted of CypA after new virus buds and
leaves the cell (57). Since the exact role of CypA in HIV-1 infection has yet to be defined,
further experimentation is necessary.
CypA directly interacts with the capsid protein (CA) and the two proteins form a
complex. This interaction is formed on CA residues 85-93, with Glycine-89 and Proline-90
making up the specific CypA binding loop (Fig. 6). The complex is stabilized by van der Waals
interactions and nine hydrogen bonds (58). Initially, this interaction was proposed to destabilize
the capsid to assist in uncoating by binding between CA, but there is little data that supports this
claim (58). Recently, evidence of a non-canonical CypA binding site on CA has been discovered.
The proposed function of this non-canonical binding site is to bind two CA together to increase
stability of the conical capsid (Fig. 6). It is also suggested that CypA binds to the most curved
CA array, promoting curved capsid assembly (59). The exact location of this non-canonical
binding site has yet to be identified, with CypA residues A25, K27, P29, and K30 being ruled out
as possibilities (Fig. 6). This binding site has been concluded to be weaker compared to the
CypA binding loop. Another possibility is that it is physically difficult for CypA to interact with
the noncanonical binding site (60). This junction between CypA and CA is significant in
understanding the protein’s contribution in HIV-1 infectivity in different cell types.
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A few HIV-1 capsid mutants are used to study the capsid’s interaction with different
proteins. These mutants are created by amino acid substitutions and include A92E, G94D, P90A,
and G89V (61, 62). The two most common mutants used to study the interaction between CA
and CypA are P90A and G89V. P90A is a mutation in the ninetieth amino acid position in the
capsid protein where proline is changed to an alanine (43, 62). Similarly, G89V is in the eightynineth position and a change from glycine to valine (40). Both mutations are located in the CypA
binding loop and disrupt the capsid protein’s ability to bind to CypA (37, 40, 43, 62). The capsid
can also be mutated to disrupt interaction with other proteins, such as TRIM5α. G94D and A92E
mutated CA cannot bind to TRIM5α (62). Changing the 94th residue on the capsid from glycine
to aspartic acid or mutating the alanine in the 92nd residue position to a glutamic acid disrupts
TRIM5α restriction interactions with the capsid. All capsid mutants are used to study capsid
interactions with key proteins. Understanding what happens when the protein cannot bind to the
HIV-1 capsid helps to reveal the relationship between the two proteins.
Many CypA research techniques either knockdown CypA within the cell or inhibit
binding of the protein to HIV-1. Using RNA interference (RNAi), CypA expression within the
cell of interest can be greatly decreased (63). A specific type of RNAi, short interfering RNA
(siRNA), can be used to control CypA expression within cells by targeting CypA RNA and
cleaving it to decrease expression. Small nuclear RNA (snRNA) can be used to disrupt unspliced
pre-mRNA by skipping exons during splicing (64). CypA can also be knocked down via
clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology. This
method uses guide RNA (gRNA) to locate and cleave target DNA. The cell then repairs the
damaged DNA, leading to a loss of function mutation (65). A frequently administered technique
to studying CypA in relevance to HIV-1 is to use the drug Cyclosporin A (CsA). This drug binds
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to CypA and blocks its interaction with CA (62). When using CsA, CypA is blocked from being
incorporated into virions (66). Both CsA and CA bind to the same hydrophobic pocket on CypA.
Because they bind in the same place, CsA acts as a competitive inhibitor against CypA (42).

Cyclophilin A and HIV
A perplexing part of studying cyclophilin A is that the protein’s effect on HIV-1
infectivity is cell type dependent. Within Jurkat cells and lymphocytes, inhibiting the interaction
between CypA and CA decreases infectivity. Yet, in HeLa cells, disrupting this same interaction
increases infectivity of HIV-1 (67). A decrease in CypA caused an increase of infectivity in
specific Old World Monkey cells: Vero cells and FRhK4 cells (68). Within dendritic cells,
presence of CypA appears to assist viral infection (43). The contradictory response of infectivity
to CypA suggests that the protein acts in a species-specific and cell-type specific manner (69).
Since the effect of CypA is variable depending on the cell type, there is a variety of proposed
roles the protein may play in HIV-1 infectivity and replication.
A possible explanation for this differing effect on infectivity in different cell types is a
variable effect on capsid stability. In some cell types, CypA appears to increase stability of the
capsid. Higher molar ratios of CypA to CA alter CA assembly and increased capsid stiffness. To
do so, CypA interacts with a non-canonical binding site to hold two CA together (59). There are
higher levels of CypA expression in HeLa cells when compared to expression in Jurkat cells
(67). Since infectivity increases in HeLa cells in the absence of CypA binding, it is possible that
at lower concentrations of CypA, there is a stabilizing effect. Opposingly, at higher
concentrations of CypA, there is a destabilizing effect (67). Therefore, the susceptibility of Jurkat
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cells to CypA depletion may be due to higher concentrations of CypA compared to other cell
types.
Some data suggest that CypA is involved in modulating cellular restriction factors. For
example, CypA plays a role in Tat palmitoylation. Tat is found in high concentrations in T-cells
and can be inhibitory to viral infection (57). Palmitoylation, the addition of fatty acids onto polar,
uncharged amino acids, controls the amount of Tat present in the cell. Tat can interact with the
membrane trafficking protein phosphatidylinositol (4,5) bisphosphate (PI(4,5) P2) and this
interaction becomes much stronger when Tat is palmitoylated (57). In fact, palmitoylated Tat has
such a strong attraction to PI(4,5)P2 that Tat expression is decreased (57). Therefore, the more
palmitoylated Tat present, the less Tat is expressed. Further, it prevents secretion, causing Tat to
accumulate on a membrane bound protein, greatly affecting membrane traffic. CypA is necessary
for Tat palmitoylation, though the exact mechanism is not known. Consequently, HIV-1 controls
Tat secretion and retention by depleting the cell of CypA via budding (57). Similarly, CypA
influences infection within human cells by blocking restriction factor 1 (Ref-1; (69)). Ref-1 is a
restriction factor that targets capsid proteins in retroviruses. Ref-1 is blocked from interacting
with the capsid because CypA-CA relations (70). Therefore, HIV-1 may have evolved to use
CypA as protection against restriction factors (71).

TRIM5α
Another cellular restriction factor that is presumably influenced by CypA is TRIM5α.
This protein acts as an antiretroviral defense against retroviruses in the cell. All members of the
TRIM family have the domains really interesting new gene (RING), B-box, and coiled-coil
domains (72). The alpha isoform of TRIM5 specifically contains a C-terminal B30.2
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(SPRY) domain, which assists in capsid recognition (73). The RING domain interacts with HIV1 CA through selective binding to ubiquitinate the capsid (72). B-Box domains allow for capsid
restriction through higher-order assembly to form trimer-of-dimers configurations (74,
75). Lastly, coiled-coil domains assist with TRIM5α self-association (76). When TRIM5α binds
to CA it oligomerizes and forms a hexagonally organized net (Fig. 7; (75)). When TRIM5α
forms a higher order assembled trimer of dimers there are two SPRY domains per
complex. SPRY domains are the domains that interact directly with the HIV-1 capsid. As one
domain binds to the capsid the other SPRY domain will rotate, making it appear as if the protein
is walking across the capsid. This movement occurs until the protein connects with another
TRIM5α to form the lattice (75).
TRIM5α is a restriction factor targets the HIV-1 capsid immediately upon entry and
disrupts reverse transcription. Although the exact mechanism is still unknown, there is evidence
of premature or restricted uncoating due to TRIM5α restriction (77). Higher amounts of
dissociated CA within the cytoplasm of old-world monkey cells expressing TRIM5α supports the
accelerated uncoating model of restriction (78). The restriction factor functions as an E3
ubiquitin ligase to protect the cell from retroviral infection (72). TRIM5α restricts HIV-1
infection by binding to the capsid, accelerating uncoating, and marking the virus for
ubiquitination. Disrupting the uncoating kinetics of the capsid exposes the viral genome
to proteosome degradation (78). Though this restriction is heavily studied in old world monkey
cells, the roll of TRIM5α is less understood in human cell lines.
Similar to CypA and its cell type specificity, TRIM5α restriction is species specific. A
study investigated the infectivity of HIV, simian immunodeficiency virus (SIV), and murine
leukemia virus (MLV) in nineteen different species’ CD4+ immune cells. Humans, owl
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monkeys, African green monkeys, rhesus macaque monkeys, cats, and dogs were some of the
species included in this test. Of the species tested, TRIM5α in old world monkey cells decreased
HIV infection. This was contrary to the higher amounts of infection found in the human cell lines
(79). Many studies focused on the difference between TRIM5α in rhesus macaque monkeys
(TRIM5αrh) and TRIM5α in humans (TRIM5αhu) due to the contrasting effect on HIV-1
infection. Replicated studies have shown that TRIM5αrh successfully restricts HIV infection but
TRIM5αhu does not (43, 62, 68, 72). The exact reason for the lack of restriction in humans has
yet to be defined, but there has been some indication that CypA may stop TRIM5αhu restriction.

TRIM5α and CypA
Recently, a link between TRIM5α and CypA has been revealed in terms of HIV-1
infection. Two studies, conducted in macrophages and lymphocytes, have linked TRIM5α to a
decrease in HIV-1 infection (43, 62). In the initial research conducted in macrophages, when
CypA-CA interaction was inhibited using P90A capsid mutants or a CypA knock down,
infection significantly decreased compared to the control sample. In the same conditions, a
TRIM5α knockdown rescued infection (43). A similar study in lymphocytes produced similar
results. Infection decreased with P90A inhibiting CypA interaction with the capsid, compared to
the wild-type capsid. Again, infectivity remained the same between P90A and wildtype capsids
in TRIM5α knockout samples (62). These results suggest that CypA-CA interactions block
TRIM5α restriction in human CD4+ immune cells (Fig. 8). This may be the reason for the
absence of TRIM5α restriction within human cells. Further studies in different cell types are
imperative to understanding this possible interaction between CypA, TRIM5α, and HIV-1
infection.
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Hypothesis and Aims
Previous studies from the Hulme lab examined the role of CypA in early steps of HIV-1
replication. Zachary Ingram’s Master’s thesis investigated the effect of CypA on HIV-1 reverse
transcription, nuclear import, and capsid uncoating in CHME3 microglial cells (80). This
research indicates that CypA enhances HIV infection in microglial cells. Treatment with CsA
decreased overall infectivity of HIV in CHME3 microglial cells (Fig. 9). Specifically, CypA
enhanced late HIV-1 reverse transcription. For the uncoating experiment, initial results revealed
less uncoating present in infected samples treated with EtOH when compared to samples treated
with CsA (80). The results also indicated an overall decrease of HIV-1 uncoating in the presence
of CypA (80). As this was a preliminary study, further research is necessary to investigate the
effect of CypA on HIV-1 capsid uncoating. There has also been recent speculation concerning
TRIM5α restriction and CypA. Multiple studies have found that inhibiting CypA interactions
with the capsid rescues TRIM5αhu restriction as mentioned previously. Studies have been
conducted in lymphocytes and macrophages so far (43, 62). To further understand the possible
connection between the two proteins and capsid uncoating, studies involving other cell types are
warranted.
With the results from previous research, there is an indication that CypA and TRIM5α
are involved in the early replication steps of HIV-1 infection. Initially it was hypothesized that
CypA destabilized the capsid and assisted with uncoating (58). But as research on this topic
progressed, it is more likely that the effect of CypA is cell type dependent. For microglial cells,
there has been evidence that CypA facilitates normal HIV capsid uncoating kinetics (80). In a
similar vein, studies have found a possible link between TRIM5α restriction and CypA. This
effect may be cell-type specific as well. The relationship between TRIM5α and CypA has been
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previously investigated in lymphocytes and macrophages (43, 62). This project will investigate
the relationship between the two proteins in microglial cells. Therefore, the goal of this thesis is
to investigate the role of CypA in HIV-1 replication. The in situ uncoating assay will be used to
analyze the effect CypA has on HIV capsid uncoating. To inhibit CypA, the drug CsA will be
used to block CypA interaction with CA. To investigate the relationship between TRIM5α and
CypA, a TRIM5α siRNA knockdown will be used in tandem with an infectivity assay. This will
allow analysis of TRIM5α restriction in the presence and absence of CypA.

FIG 1 Structure of Mature Virion. Image depicts a mature HIV-1 virion. Gp120 and gp41 are
indicated in red. The matrix protein is in dark blue, capsid protein is in green, nucleocapsid is
orange triangles, and the viral RNA is pink. Modified from (13).
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FIG 2 HIV-1 Replication Cycle Schematic. Replication begins with virion binding. Nine steps
occur for successful virion replication. This progress infects the cell with HIV-1 and produces
viable virus (30).

FIG 3 HIV-1 Mature Capsid Structure. The mature capsid is enlarged and shows the hexamers
in orange and pentamers in yellow. The hexamers and pentamers are made up of monomers.
Modified from (13)
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FIG 4 Immediate, Biphasic, and NPC Uncoating Models. (A) In immediate uncoating the
capsid disassociates immediately upon entry. (B) Biphasic uncoating models uncoating in the
cytosol while the capsid travels towards the nucleus. (C) Nuclear pore complex uncoating
shows uncoating occurring at the nuclear pore (13).
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FIG 5 Nuclear Uncoating Model. Image depicts the viral capsid fully uncoating after entering
the nucleus (39).

FIG 6 CypA Bound to CA. Structure of CypA (blue) bound to two HIV CA (pink). Proposed
noncanonical binding site is bound on the right and the CypA binding loop on the left. Image
indicates with arrows the residues involved in the interaction between the proteins. Modified
from (60).
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FIG 7 TRIM5α Bound to the HIV-1 capsid. TRIM5α (purple) bound to the viral capsid
(green). Image shows the hexamers (dark green) and pentamers (light green) that make up the
capsid. Modified from (35).

FIG 8 TRIM5α Binding to the Viral Core in Absence of CypA. Proposed model of CypA
blocking TRIM5α restriction in human cells. CypA is in pink, TRIM5α depicted as a complex
composed of green, red, blue, and yellow portions, the viral core is dark blue and dark green
(62).
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FIG 9 Infectivity Results With Treatment of CsA or EtOH. Black line is CHME3 cells treated
with EtOH. Dotted gray line is CHME3 cells treated with CsA. The percent of GFP positive
cells indicates the percentage of infected cells (80).

25

METHODS

Cell Culture and Maintenance
All research was conducted in accordance with continuing IBC protocols 2022-02.3 and
2022-02.4. The most recent update of these protocols were approved on 2/24/2022 (see
Appendix A). Institutional Review Board approval was not required for use of the human cell
lines used in this research. Cultured cells were kept in a tissue culture incubator at 37°C and 5%
CO2. Cells were split once they reached approximately 80% confluence. 293T HEK cells and
CHME3 microglial cells were cultured in 100 x 20 mm Falcon culture dishes (Corning).
Media for the 293T cells was comprised of 1X Dulbecco’s Modified Eagle Medium (DMEM;
Corning), and 10% fetal bovine serum (FBS; R&D Systems), with 100 U/mL penicillin, 100
U/mL streptomycin, and 292 µg/mL L-glutamine (1% PSG; Corning). CHME3 media was made
of 1X DMEM, 1X PSG, 5% FBS, 1% PSG, and 0.91 mM Sodium Pyruvate (Corning).
The 293T HEK cell line was provided by the Hope lab at Northwestern University. To
split 293T HEK cells, media was removed from the dish and 1 mL of trypsin (Corning) was
added to the cells. The trypsin was aspirated off and 1 mL of trypsin was added to the dish then
removed. The dish was then placed in the incubator and the new plate was labeled and prepped
by adding 10 mL of fresh media. Once cells were lifted from the bottom of the plate, the cell
plate was treated with 10 mL of fresh media. Cells were gently pipetted to break up clumps.
Lastly, 1 mL of the cell solution was added dropwise into the new plate.
The CHME3 cells were provided by the Naghavi lab at Northwestern University (81). To
split CHME3 cells, the cells were washed with 5 mL of 1X phosphate buffered saline (PBS;
Corning). Next, they were treated with 3 mL of trypsin to remove the cells from the bottom of
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the plate. As the cells briefly incubate in trypsin, the new plate was labeled and prepped by
adding 10 mL of fresh media. The plate with cells was then treated with 7 mL of media to
neutralize the trypsin. Cells were then pipetted to break up any clumps and 1.5 mL of the cell
solution was added dropwise to the new plate.

Making Dual Labeled Virus
Cells at 80% to 90% confluency were seeded out into a 10 cm tissue culture dish by
adding 1.5 mL cells into the dish. Typically, one confluent plate of cells can yield five plates of
transfected cells. The following day, the transfection solution made up of DMEM, HIVGFP proviral plasmid, CMV-VSV-g plasmid, GFP-Vpr plasmid, S15-tomato plasmid, and 40 µL
per reaction of PEI transfection reagent (Polysciences) was mixed. The amount of plasmid used
to make the dual labeled virus stocks was varied to optimize labeling (Table 1). The solution was
incubated at room temperature for 15 minutes and then added to the plates dropwise. Cells were
then stored in the tissue culture incubator for 24 hours. The following day 10 mL of fresh 293T
media was added to each plate and allowed to sit for 16 to 18 hours. Last, virus was harvested,
and a gown and double gloves were worn to avoid contamination. Media from a transfected plate
was transferred to a conical tube. Next, the filtering apparatus was assembled. To do so, the
plunger was removed from a 20 mL syringe (BD Biosciences) and a Millex syringe driven filter
unit was screwed to the bottom of the syringe. The media was placed into the syringe and slowly
forced through the filter into a 50 mL conical tube. This step was performed with caution as to
not spill any media containing virus. The filtered virus was aliquoted into labeled cryovials and
stored at -80°C. Any material that encountered the virus was thoroughly bleached to kill any
virus producing cells or any remaining virus.
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Virus on Glass
To test viral labeling, virus was plated onto coverslips to analyze its fluorescence. To
begin, glass coverslips soaked in 70% ethanol were plated into 24-well plates. Two coverslips
per virus tested was used, one for staining and one for background control. Coverslips were
washed with 100µL of 1X PBS three times and then treated with 0.01% poly-L-lysine (SigmaAldrich) for fifteen minutes. This treatment gives the coverslips a positively charged surface for
the negatively charged virus to adhere to. During the incubation period, a 1:10 virus dilution was
made in CHME3 media. Once the incubation time lapsed, coverslips were washed three times
with 1X PBS. The washing buffer was removed via aspiration and 400 µL of diluted virus was
added to each coverslip. Next, the 24-well plates were spinoculated at 1200 x g for 1 hour at
16°C. Once complete, the virus was removed, and samples were rinsed with 1X PBS. Coverslips
were treated with 4% paraformaldehyde for fifteen minutes at room temperature. Samples, again,
were rinsed three times with 1X PBS. Finally, 1X PBS was added to each well and samples were
covered in aluminum foil and stored at 4°C overnight. On day 2, coverslips were stained with
primary antibody, 241-D to target CA, and incubated overnight. Secondary antibody (Jackson
ImmunoResearch) that targeted the primary antibody and contained the Cy5 tag followed on the
consecutive day. Primary and secondary antibody staining protocol was the same as the in situ
assay staining, as described below. Similarly, coverslips were mounted onto slides and stored at
4°C until imaging.

In Situ Uncoating Assay
Day 1. The first day began with removing glass coverslips from a 70% Ethanol bath and
placing them, one at a time, into individual wells of a 24-well plate (Falcon, Corning). This was
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performed in the tissue culture hood. Coverslips were next washed with 500 µL of 1X PBS three
times. Following the wash, coverslips were treated with 500 µL of 0.1% Gelatin (Millipore
EmbryoMax Specialty Media) and incubated at room temperature for 30 minutes. While the
coverslips sat in the gelatin, CHME3 cells were split according to protocol. The remaining cells
were counted using a hemocytometer. A diluted cell mix was made to plate 120,000 cells per
coverslip. Once the coverslips were done incubating, the gelatin was removed and 500µL of the
cell solution was added to the appropriate wells.
Day 2. To continue the In Situ assay, the plated cells were infected with virus in the
tissue culture hood and the coverslips fixed on a time-course. All steps following were
performed in the minimal amount of light to avoid photobleaching. A virus infection
solution was made for CsA wells, the BafA well, and EtOH wells according to the well plate
template (Fig. 10). Dual labeled virus was used at a 1:10 or 1:5 concentration. To make the
solution for CsA samples 2875.20µL of cell media, 3.20µL of 1X DEAE Dextran used at 10
µg/mL, 1.60µL of CsA (EMD Millipore) at a concentration of 2.5 µM, and 320µL of dual
labeled virus were combined. The EtOH solution was made up of 2875.20µL of cell media,
3.20µL of Dextran, 1.60µL of EtOH, and 320µL of dual labeled virus. Last, the BafA control
virus solution was made of up 718.40µL of media, 0.80µL Dextran, 0.40µL EtOH, 0.80µL BafA
at a working concentration of 0.02µM, and 80µL dual labeled virus. To each well, 400 µL of the
viral solution was pipetted into the appropriate well. After that, the plates were placed into the
centrifuge to spinoculate at 1200 x g and 16°C for 1 hour. This synchronizes infection by
bringing all of the virions to the extracellular membrane to begin endocytosis. Fusion does not
occur until warm media is added. Next, cells are removed from the centrifuge and rinsed with
500µL 1X PBS. After the spinoculation, 400µL of warm CHME3 media was added to each well.
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The BafA coverslip received a 400µL of a media-BafA solution made up of 800µL media and
0.80µL of BafA. No additional EtOH or CsA was added to the remaining coverslips. At this
time, the 0-hour coverslips were fixed by adding 4% paraformaldehyde to the wells and
incubated at room temperature for 15 minutes. Then, the cells were washed with 500µL of 1X
PBS three times. The remaining coverslips were fixed at 1-, 2-, 3-, and 4-hours post infection.
The fixed coverslips were covered with 500µL 1X PBS and stored overnight at 4°C.
Day 3. The next day was performed on the lab bench. To begin, the staining box was
prepared by wetting strips of paper towel and lining the parameter of the box to keep the
coverslips from drying out during the staining process. In a dark room, the 1X PBS was removed
from the coverslips and, using tweezers, the coverslips were removed from the 24-well plate and
placed into the staining box. All coverslips were immediately covered in 100 µL of 1X PBS.
Once all coverslips were transferred, they were incubated in permeabilization solution for 15
minutes at room temperature. This solution was comprised of 0.05% Triton X in 1X PBS. During
incubation, the lid to the box was closed to avoid photobleaching. Once finished, coverslips were
washed with 100µL 1X PBS four times with a 5-minute incubation on the fourth wash. After
that, coverslips were incubated in 100µL of blocking solution, made of 10% FBS, for 30 to 40
minutes. During the incubation time, the primary antibody solution, with the antibody 241-D at a
4000X concentration, was mixed using the equation to achieve a 1X concentration (Fig. 11).
This antibody targets CA that makes up the HIV-1 capsid. Finally, post incubation, the antibody
solution was added to all coverslips, except the secondary only control. The black staining box
was carefully placed into 4°C and stored overnight. ProLong Glass Antifade Mountant
(Thermofisher), a gel mount, that is stored at 4°C was brought up to room temperature to use the
next day.
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Day 4. The last day started with mixing the secondary antibody solution, using antihuman 647 antibody (Jackson ImmunoResearch) at a 400X concentration. This antibody targets
the primary human antibody used in Day 3 and contains the Cy5 fluorescent tag that allows for
visualization of intact capsid. The equation was used to achieve a 1X concentration. (Fig. 12)
The staining box was removed from the refrigerator and placed on the lab bench. Coverslips
were washed with 100 µL 1X PBS. Following were three washes in 1X PBS for 5 minutes each.
Next, the secondary antibody solution was added to each coverslip. The solution was allowed to
incubate for 1 hour at room temperature. After the time passed, coverslips were washed with 1X
PBS three times for 5 minutes each. Lastly, gel mount was used to fix the coverslips onto glass
slides. The mount used preserves fluorescence to prevent photobleaching. The slides were
allowed to dry for 2 to 3 hours and then stored at 4°C for up to two weeks before imaging.
Imaging With Microscope. To image the in situ assay coverslips, a Leica SP8 DMI8
confocal microscope was used in tandem with the Leica Application Suite X (LASX) software.
To start, the microscope and the computer were turned on. Next, once all hardware is on, the
microscope software was opened. Within the software, “Acquire” was selected and 2 sequential
scans were added, for a total of 3. Each sequential scan changes the wavelength to analyze the
three fluorescent tags. The confocal microscope takes Z stack images at each wavelength. Next,
for sequential scan 1, GFP was selected and adjusted from 15 to 30 percent transmission. Scan 2
was the user defined dTomato, and scan 3 was the computer setting Cy5. Once the software was
set up, the slides with the coverslips were set under the microscope. A cell was found manually
using the light of the microscope, then the topmost Z section of the cell and bottom most Z
section were selected. Once complete, “take picture” was selected and the microscope took an
image of the cell. Each image was comprised of an average of 30 Z sections. This was repeated
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10 times per slide at different locations on each coverslip. Once all images were taken, they were
saved onto the computer.
Data Analysis. To begin analysis for each image, the background fluorescence had to be
manually removed, in a process called thresholding. The uninfected control sample was used to
determine the amount of background GFP and dTomato fluorescence present. The secondary
antibody only control was used to find the amount of background caused by the Cy5 signal.
Using the thresholds, the background was removed for all experimental samples and samples
were saved as TIFF images.
Following download, the images were analyzed using a semiautomatic counting software.
Using the ImageJ Overlap Intensity macro plugin, the fluorescence of each image was quantified
(82). This software uses colocalization analysis to measure the overlap of two signals. To do this,
it locates all GFP signals on the image and labels them as a region of interest (ROI). It then
measures the intensity of Cy5 and dTomato signals in each ROI. Images were able to be
processed in batches that were organized by sample. The maximum fluorescence for each ROI
was saved in a Microsoft Excel sheet for further analysis. Using Excel, the mean maximum
fluorescence of Cy5, percent uncoating, and percent fusion were calculated and compared
between samples.

siRNA TRIM5α Knockdown
Day 1. To begin the knockdown, CHME3 cells must be 60% to 80% confluent in the
culture dish. Two cultures of cells were prepared to ensure there were enough cells. Before
starting, all equipment was cleaned using a 70% ethanol solution. Cells were split according to
the protocol above. The remaining cells from both dishes were saved in a 50 mL conical tube and
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15 µL of the cell solution was used to count using a hemocytometer. Next, the number of cells
needed to plate 1.7x105 cells per well in a 6-well plate was calculated. Using the calculated
amount, the diluted cell solution was mixed, and 2 mL of the cell solution was aliquoted into
each well of two 6-well plates. The plates were incubated overnight.
Day 2. All equipment was treated with RNAase Zap (Fisher Scientific) and placed under
an ultraviolet light for 15 minutes prior to the experiment. The following day the cells were
transfected with siRNA pools targeting TRIM5α and GAPDH (Horizon). As controls, a
nontarget siRNA (Horizon) and a no siRNA transfected were used. Once treatment was finished,
each siRNA solution was mixed for each appropriate sample. Two Eppendorf tubes were used
for each sample, labeled tubes A and B. To tube A, 50 µL of OPTIMEM media was added. To
tube B, 100 µL of OPTIMEM media was added. Next, 4 µL of lipofectamine RNAiMax
(Invitrogen) was added to tube A and mixed by tapping. Tube B then received 3 µL of the
appropriate siRNA duplex (100pmol/µL) and mixed by tapping. Both tubes were incubated at
room temperature for 5 minutes. Next, tube A contents were added to tube B, mixed by pipetting,
and incubated at room temperature for 20 minutes. During incubation, the CHME3 media was
aspirated from the cells in the two 6-well plates and replaced with 1 mL of OPTIMEM media.
Each well was labeled for TRIM5α, GAPDH, NT4, or no siRNA. After the 20 minutes, the
siRNA duplex mixtures were added to the appropriate wells in both 6-well plates in a dropwise
manner and each plate was rocked back and forth to mix the wells. The plates were placed in the
incubator. Next, four hours later, the transfection media was replaced with 1 mL warmed DMEM
media that does not have PSG and samples were incubated overnight.
Day 3. The transfected samples from one plate were transferred to two 96-well plates,
one for CsA and one for EtOH. One 6-well plate was saved for RNA isolation later. To transfer
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samples to a 96 well plate, the media was removed from the cells, and they were washed with 2
mL of 1X PBS. The PBS was removed, and 1 mL of trypsin was added to release cells from the
bottom of the plate. Once the cells lifted from the bottom of the plate, 1 mL of warmed CHME3
media was added to each well and the media was pipetted to break any clumped cells. For each
sample run, the cells were placed in a separate conical tube and counted using a hemocytometer
to determine the number of cells per transfection sample. Using the number of cells in each tube,
the amount needed to have 6,000 cells per well was calculated. A solution was mixed for each
condition using the appropriate cells and CHME3 media. To the 96-well plate, 100µL of this cell
solution was added to the appropriate wells, using the multichannel pipette. Cells were plated
according to the schematic (Fig. 13) and the plate incubated overnight.
Day 4. The cells were infected with HIV-GFP reporter virus that fluoresces infected
cells. In the 96-well plate, an infectivity dilution was used to analyze infectivity. To start, 1X and
2X media was made for both CsA and EtOH. The 1X media was made up of 6mL of cold
CHME3 media, 3µL of 2000X polybrene, and 3µL of either 2000X CsA or EtOH. The 2X media
was made up of 1mL of cold media, 1µL of 2000X polybrene, and 1µL of 2000X CsA or EtOH.
To the first column of each plate, 100µL of the appropriate 2X media was added using the
multichannel. The remaining columns received 100µL of 1X media to the CsA and EtOH 96well plate. Next, the virus solution was mixed to create the serial dilution. An example for the
1/16th serial dilution is a viral mix made up of 1.75 mL of cold CHME3 media and 250µL of
HIV-GFP virus. Once mixed, 100µL of the solution was added to the first column for each plate.
For the serial dilution, 100µL from column 1 was added to column 2 and mixed by pipetting
gently. This process was repeated for all columns except the last one to keep an uninfected
control. For last column to receive virus, 100µL was discarded into bleach for the proper
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dilution. Once virus was added to the cells, the plate was centrifuged at 1,200xg for 1 hour at
16°C. While the 96 well plates were spinning, RNA was isolated from the cells in the 6-well
plate with the transfected cells according to protocol previously described and samples were
stored -20°C. When spinoculation was complete, the virus solution was replaced with warm
media that contained 3µL CsA or EtOH for all wells and the plate was placed into the incubator
overnight.
Day 5. Cells were viewed under a light microscope to ensure they were still healthy and
alive. The plate was incubated overnight.
Day 6. On the last day, the cells were harvested. To do this, 100µL of cell fix solution
was made up that contained one part paraformaldehyde to one-part 1X PBS mixed in a 15 mL
conical tube. Cells were lifted from the bottom of the plate, as before, using trypsin. The samples
sat in trypsin longer to naturally release from the bottom of the well because cells were fragile
after infection. Cells were resuspended in the trypsin and 100 µL of cell fix was added to each
well using the multichannel. The plate was then sealed with parafilm, wrapped in aluminum foil
to avoid photobleaching of the virus, and stored at 4°C for a minimum of 4 hours. Once finished,
the cells were ready for flow cytometry.

Flow Cytometry
To analyze the cells for infectivity, the Accuri C6 flow cytometer (BD Biosciences) was
used. From the 96-well plates with siRNA, 2 wells of the same sample were combined into 1
glass tube for a total of 400µl of sample into each tube. If not performing flow cytometry the
same day, samples were stored at 4°C. Next, the flow cytometer and the software were turned on
according to machine guidelines. An empty tube was placed on the sip and the machine was
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backflushed. The template “Pekic” was used for siRNA analysis. This template has gated graphs
that select the amount of living cells and GFP positive cells in each sample analyzed. The
software was set to 10,000 events or 120µL and a fast run. After that, the sample was placed on
the sip and run was selected. The negative control line on the graph for the uninfected sample
was moved to between 0.1% and 0.0% to remove background for each sample. Data in the
analysis file from plots 1 and 2 in the template were saved.

TRIM5α Primer Cloning
RNA Isolation From CHME3 Cells. To isolate total RNA from CHME3 cells the
Qiagen RNeasy Plus Mini kit was used. The standard protocol was followed for this kit. Before
starting, 10µL of B-mercaptoethanol was added to 1 mL of Buffer RLT Plus in the chemical
hood. To begin, CHME3 cells were split according to the protocol above. The remaining cells
were added to a 15 mL tube and 15 µL used to determine the number of cells via a
hemocytometer. Approximately 10,000 cells were transferred to a new 15 mL tube and
centrifuged at 300 x g for 5 minutes to pellet the cells. Remaining media in the tube was
aspirated for disposal.
Next, the cell pellet was loosened by flicking the tube and 350 µL of Buffer RLT plus
was added to lyse the cells and the sample was pipetted to mix the solution. To homogenize the
lysate, the total cell solution was added directly to the purple QIAshredder spin column (Qiagen)
in a 2 mL collection tube. The sample was centrifuged for 2 minutes at maximum speed and the
flow through saved. Following, the flow through was added to a white and purple gDNA
Eliminator column and centrifuged for 30 seconds at 8000 x g or until all liquid has passed

36

entirely through the column. Next, 350 µL of 70% ethanol was added to the flow through and
mixed via pipetting.
To a pink RNeasy spin column, 700 µL of this solution was added and centrifuged for 15
seconds at 8000 x g, and the flow through was discarded. To the same pink column, 700 µL of
Buffer RW1 was added and centrifuged as before and the flow through was discarded. Again, to
the same RNeasy spin column, 500 µL of Buffer RPE was added and centrifuged again for 15
seconds at 8000 x g, and the flow through was discarded. This step was repeated and centrifuged
for 2 minutes at 8000 x g or until the pink column was dry. The pink column was placed in a new
collection tube and centrifuged at full speed for 1 minute to remove any residual liquid. Next, the
column was placed in a 1.5 mL Eppendorf tube for collection and added 50 µL of RNase free
water and centrifuged for 1 minute at 8000 x g. The final total CHME3 RNA sample was stored
at -20°C. Total RNA concentration was determined using a nanodrop spectrophotometer.
Reverse Transcription Reaction With Total RNA. To start primer development, the
RNA was reverse transcribed to cDNA (Fig. 14). For this reaction, the reagents in table 2 were
combined and samples were pipetted to mix. A negative reverse transcription control was made
up by replacing reverse transcriptase with water. Samples were incubated for 1 hour at 37°C.
Next, the cDNA was amplified using PCR.
PCR Amplification. cDNA was amplified using TRIM5α primers A, C, and E. A master
mix for PCR products was mixed using SsoFast EvaGreen Supermix (Bio-Rad) protocol or
GoTaq Green Master Mix (Promega). Both protocols were used in an attempt to optimize
amplification. GoTaq Green was more efficient and used for repeated experiments. PCR
products were run on a 3% agarose gel to confirm amplification using a gel electrophoresis rig.
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Gel Electrophoresis. The 3% gel was made by combining 75 mL of 1X TAE with 2.25 g
of agarose. The solution was heated and 2.25 µL of ethidium bromide was added. The gel was
allowed to cool slightly and then poured into the gel rig to form the wells. Once the gel was solid
it was properly positioned in the rig and 1X TAE was poured into the gel rig up to the fill line.
The samples were pipetted into wells. The gel rig was run at 100V for 45 minutes and imaged on
a gel reader.
PCR Clean Up and Ligation Reaction. PCR products were cleaned up using two kits:
QIAquick PCR Purification Kit (Qiagen) and Wizard SV Gel and PCR Clean-Up System
(Promega). The Wizard kit was used because reagents in the Qiagen kit had expired. The PCR
products were purified using the protocol for the appropriate kit. Once purified, the samples for
TRIM5α primers A and C underwent pGem Teasy ligation reactions (Promega). The reagents
mixed together for the ligation reaction were 5µL of cutsmart buffer (NEB), 1.5µL of nuclease
free water, 2µL of purified PCR inserts, 1µL of ligase, and 0.5µL of pGem Teasy vector. The
solution was incubated overnight at 4°C.
Transfection of Vector Into HB101. To begin transformation, 100 µL of competent
HB101 cells (Promega) were thawed slowly on ice for 15 minutes. Next, 2 µL of the ligation
solution was added into the cells and the tube was flicked to combine. After, the cells chilled in
ice for 10 minutes. Immediately following, samples were heat shocked in a bead bath set to 42°C
for 45-50 seconds then the tube was put back in ice for 2 minutes. To the tube of HB101 cells,
900 µL of LB media was added. The samples were placed on a shaker set to 220 RPM for one
hour at 37°C. While shaking, LB-Amp plates were placed in the incubator to warm. After the
samples were done shaking, 100 µL of the cell solution were plated onto the LB plate. The
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remainder of the solution was stored at 4°C. The plated cells were placed into the incubator at
37°C overnight.
Bacterial Culture. Of the colonies that grew from the transfected HB101 cells, one
single colony was selected to grow up in a culture. To culture the cells, 3 mL of 0.1% ampicillin
media mix was aliquoted into culture tubes for each sample. An example of master mix was 32
mL of LB media with 32 µL of ampicillin added. Next, near a flame, one colony was put onto
the end of a pipette tip and the tip was ejected into the culture. The samples were placed into the
shaker set to 220 RPM at 37°C overnight.
Miniprep. The following day, samples were put through a miniprep to isolate the
plasmids. The Qiagen Qiaprep miniprep kit and protocol for the kit using a microcentrifuge was
used. Lyseblue was not added to the samples, so the protocol followed did not include that
reagent’s steps. EB buffer was used to elute at the end. Samples were stored at 4°C.
EcoR1 Restriction Digest. After the miniprep, a restriction digest was implemented. The
1X master mix was made up of 3 µL of cutsmart buffer (NEB), 0.5 µL of EcoR1 (NEB), and
16.5 µL of water. Next, 20 µL of master mix was added to an Eppendorf tube labeled per each
sample. To each tube, 10 µL of the appropriate miniprep DNA was added to the digest master
mix. Samples were incubated for 1 hour at 37°C. While samples incubate, gel electrophoresis
was set up as detailed above. After incubation, the digest samples were each mixed with 6 µL of
loading dye and 25 µL of each sample was loaded into the gel. The gel was run and imaged
using a gel reader.
Primer Efficiency: qPCR. To calculate primer efficiency, a serial dilution of the pGemTeasy-TRIM plasmid had to be run through qRT-PCR. The serial dilution was made up of 107,
106, 105, 104, 103, 102, 101 plasmid DNA with 107 being the miniprep DNA stock solution. For
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each tube, starting with 106, 45µL of water was aliquoted into each tube. Then, 5µL of the
previous tube was added. Therefore, 5µL of 107 was put into 106, then 5µL of 106 was put into
105 and so on. Next, the master mix was made according to the number of tubes used. For
example, for 24 qPCR reactions, 241.92µL of water, 288µL of iTaq master mix (Bio-Rad),
8.64µL of forward primer (Table 3), and 8.64µL of reverse primer (Table 3) were mixed together
to make the master mix. Next, 19µL of the master mix was aliquoted into the qPCR tubes. Once
complete, 1µL of each serial dilution sample was put into the appropriate tube. Instead of sample
in the last tube, 1µL of water was added as a control. Finally, the tubes were run on the qPCR
machine using the iTaq protocol. For the cycling conditions, the polymerase activation was set at
95°C for 20-30 seconds, denaturation at 95°C for 2-5 seconds, annealing/ extension at 60°C for
15-30 seconds. This was run for 25-30 cycles. Melt curve analysis was from 65°C to 95°C in
0.5°C increments for 2-5 seconds per step. Results were saved in a Microsoft Excel sheet for
later analysis.

TABLE 1 Amount of Plasmid Used for Dual Labeled Virus Stock
Plasmid
3-7-20
3-7-20
3-7-20
2-13-21

2-13-21

2-13-21

Stock 1

Stock 2

Stock 3

Stock A

Stock B

Stock C

HIV-GFP

3.70µg

3.70µg

3.70µg

3.70µg

3.70µg

3.70µg

GFP-Vpr

1.00µg

1.00µg

1.00µg

1.00µg

1.50µg

1.50µg

S15-tomato

5.50µg

5.50µg

5.50µg

5.50µg

5.50µg

2.00µg

VSV-g

1.09µg

1.09µg

1.09µg

2.10µg

2.10µg

2.74µg
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TABLE 2 Total RNA Reverse Transcription Reaction
Reagents
Concentration

Amount

5X

4 µL

MgCl2

50 mM

2 µL

dNTPs (Promega)

10 nM

2 µL

RNasin (Promega)

-

1 µL

AMV reverse transcriptase (Promega)

-

1 µL

Random Hexamers (Promega)

-

2 µL

CHME3 RNA

1.3 µg/µL

0.76 µL

Deionized H2O

-

7.24 µL

AMV Buffer (Promega)

TABLE 3 Primer Table
Primer

Sequence

Forward Primer GAPDH

5’-GCACCGTCAAGGCTGAGAAC-3’

Reverse Primer GAPDH

5’-GCCTTCTCCATGGTGAA-3'

Forward Primer TRIM5α-A

5’ -TTCTGTACAGCACCTCTTGTCC-3’

Reverse Primer TRIM5α-A

5’-AAAGAAGGGAGACAGCAAGGAAA-3’

Forward Primer TRIM5α-C

5’-ACCTCTTGTCCAGGTGCAT-3’

Reverse Primer TRIM5α-C

5’-ATTGGGGACAATATGGCACAAG-3’

Forward Primer TRIM5α-E

5’-TCTTGTCCAGGTGCATCTCATA-3’

Reverse Primer TRIM5α-E

5’-ATAGAAAGAAGGGAGACAGCAAGG-3’
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FIG 10 24-Well Plate Schematic For the In Situ Uncoating Assay. CsA treated coverslips are
depicted in blue, EtOH are in purple, and controls are in green.
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FIG 11 Primary Antibody Equation. The amount of primary antibody needed for staining was
calculated using the dilution equation C1V1 = C2V2. The starting concentration was 4000X.
The ending concentration was 1X. The final volume was 100 µL per coverslip, accounting for
one extra coverslip. The final volume was adjusted if necessary to be above 0.2 µL.

FIG 12 Secondary Antibody Equation. Using C1V1 = C2V2, the amount of secondary
antibody was calculated. The starting concentration was 400X and the final was 1X. The
ending volume was 100 µL per coverslip plus 100 µL.

FIG 13 96-Well Plate Schematic. Image depicts the set up for the 96 well plate used in the
siRNA knockdown. Two plates were prepared, one for CsA and one for EtOH. This plate
shows an example serial dilution. In the plate, T represents TRIM5α siRNA, G is GAPDH
knockdown, NT is the NT4 pool siRNA and NS is no siRNA.
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FIG 14 Method Flow Chart for Aim 2. The chart shows the process used to test the effect of
CypA and TRIM5α for aim 2.
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RESULTS

Effect of CypA on HIV-1 Uncoating
I hypothesize that CypA assists with uncoating. To investigate the effect of CypA on
uncoating in microglial cells, the in situ uncoating assay was used. To block interaction between
CypA and CA, samples were treated with the inhibitor CsA. It is expected that microglial cells
treated with CsA will report a higher amount of CA compared to cells treated with EtOH.
Description of the In Situ Uncoating Assay. The in situ uncoating assay allows
uncoating to be analyzed within infected cells. CHME3 cells were fixed on a time course after
infection with dual labeled VSV-g pseudotyped virus. To make the dual labeled virus four
plasmids are transfected into 293T cells. The HIV-GFP plasmid contains all viral proteins
necessary for replication except has a frameshift mutation to disrupt the viral envelope gene and
blocks formation of infectious virus. The VSV-g plasmid produces the env protein to allow the
virus to infect via endocytosis and produces single use virus (83). Typically, HIV enters the host
cell through binding and fusion with the cell membrane, not by endocytosis. Despite this
difference in infection, uncoating occurs as it would in wildtype HIV (38). GFP-Vpr labels the
viral complex and allows for visualization of the viral particles within cells (Fig. 15). The HIV-1
membrane itself has also been labeled with a s15-dTomato fluorescent protein. (dTomato; Fig.
15) (84).
After fixation, samples undergo primary and secondary antibody staining that targets CA
of the HIV-1 capsid. The secondary antibody is Cy5 fluorescent tagged. Samples are imaged
using fluorescent microscopy to reveal presence of the viral complex, viral membrane, and CA
present during each time point. In the images, the viral complex located within the capsid
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appears green, due to GFP-Vpr; viral membranes are red because of dTomato labeling; and CA
is blue, due to the Cy5 secondary antibody staining (Fig. 15). Overlap of dTomato and Cy5
indicates virus that has neither fused nor uncoated (Fig. 15). In this assay the amount of CA
signal present in the hours following HIV-1 infection is tracked to reveal the effect CypA has on
uncoating.
Analyzing Dual Labeled Virus Stocks. To ensure that the virus stocks produced in the
lab had the proper labeling, each stock was analyzed. By mounting the virus onto glass slides and
imaging each sample, the amount of fluorescence from each tag was calculated as a percentage
(Fig. 16). Percent dTomato is the percent of GFP labeled virus that also has the dTomato label.
The threshold for viable stock is 80% dTomato, indicating that 80% of GFP labeled virions also
contained dTomato labeling. It is important to know the amount of dTomato membrane labeling
compared to GFP labeling because it can be taken into consideration when analyzing presence of
membrane in experiments that use this virus. When making the virus, some cells received a
varied amount of each plasmid in an attempt to optimize labeling. The three viral stocks made on
3-7-2020 all received the same amount of each plasmid. The stocks made on 2-13-2021 received
varied concentrations of each plasmid (Table 1). All stocks, except EW 3-7-20 batch 2, meet or
exceed the 80% threshold for dTomato labeling (Fig. 16). The EW 3-7-20 batch 2 reached 75%
dTomato labeling and the remaining virus stocks met the threshold, so all stocks were
determined usable for further experiments.
The virus was also analyzed for the amount of Cy5 staining to determine the amount of
CA detectable for each stock. The stocks made on 3-7-20 each had Cy5 staining at 60% to 84%
(Fig. 16). This means that at least 60% of virus that contained the GFP label had detectable Cy5
signal from antibody staining. Interestingly, all stocks made on 2-13-21 show considerably lower
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Cy5 fluorescence when compared to virus made on 3-7-20 (Fig. 16). For the February stocks, all
Cy5 signal detection was below 20%. From this analysis, stocks 3-7-20 batch 2 and 2-13-21
batch A were selected to be used in future experiments.
Assay Development and Controls. For the in situ uncoating assay, microglial cells were
infected with dual labeled virus in the presence of CsA or ethanol (EtOH) and fixed on a time
course from 0 to 4 hours post infection. Samples were then stained with antibody for CA and
imaged (Fig. 17). The semi-automatic overlap intensity counter in ImageJ was used for image
analysis (82). A total of three in situ uncoating assays were conducted and analyzed. Data from
these assays were combined to visualize trends. The controls include a Bafilomycin A (BafA)
treated sample used as a fusion inhibitor control, a secondary antibody only coverslip, and an
uninfected sample. The drug Bafilomycin A is a V-ATPase inhibitor and blocks VSV-g HIV
fusion. It achieves this by blocking endosomal fusion of the VSV glycoprotein to the cell
membrane (85).
To analyze the in situ assay results, the maximum fluorescent intensity of Cy5 was
calculated for each virion marked by GFP-Vpr. This number reveals the amount of CA present in
each virus and can be used to see how much uncoating has occurred in each condition. To avoid
counting capsid from unfused virus, only Cy5 signal from virus without dTomato signal was
included in uncoating analysis. The average CA signal, or mean maximum fluorescence
intensity, was then calculated for each condition for each time point.
Effect of CypA on Uncoating. To analyze the amount of CA present in each condition,
the data was pooled into one scatterplot (Fig. 18). The BafA fusion control had an average CA
signal detection of 160, which is relatively similar to the detection of 152.1 and 164.7 for EtOH
treated samples at 1- and 2-hours respectively. Combined data from all assays shows a change in
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the mean maximum Cy5 signal in the CsA treated samples compared to the EtOH samples. The
CA signal is higher in CsA compared to EtOH at the 0-, 1-, 2- and 3-hour time points (Fig. 18
and Table 4). The 1-hour time points are barely dissimilar, with a difference of 2.4 (Table 4).
The trend set by the 1-, 2-, and 3-hour time points is switched at 4-hours post infection where
there is more CA signal detected in the EtOH condition compared to the CsA condition (Fig. 18).
At this final time point, there is more CA signal detected in the EtOH condition compared to the
CsA condition. This data indicates that when CypA is able to bind to the HIV-1 capsid, there is
less CA present for time points 1-, 2-, and 3-hours post infection.
Of the combined data, the greatest difference between the CsA and EtOH conditions is
found in the 3-hour time point (Fig. 18 and Table 4). CsA treated samples reported a Cy5 signal
of 157.7 and EtOH samples reported 92.92 (Fig. 18 and Table 4). It is important to mention that
for this time point specifically, the CsA data is made up of three experiments, while the EtOH is
only made up of data from two assays. Despite this difference, this trend can be trusted because
similar results were produced from the two complete experiments for the same time point (Table
4). The 3-hour time point from the June experiment showed a signal of 162.3 for CsA and 91.72
for EtOH. Similarly, the February experiment yielded a signal of 120.9 for CsA and 94.17 for
EtOH. Therefore, the result of 157.7 for CsA and 92.92 for EtOH is expected for this time point.
Overall, Cy5 levels, that measure the amount of CA present, are consistently greater in CsA
conditions compared to EtOH.
When analyzing each in situ uncoating assay separately, there are some trends found in
all three. The BafA fusion control had similar results for all experiments with Cy5 signal
detection of 171.5, 130.9, and 176.9 for June, February, and March respectively (Fig. 19 and
Table 4). For the 0-hour time point, there was a higher signal in the CsA condition compared to

48

the EtOH for the June, February, and March experiments, with March having the largest
difference (Fig. 19). Interestingly, the 0-hour time points all reported average signal detection
numbers below 100 for all experiments (Fig. 18 and Table 4). The 1-hour time point was not as
consistent. The June and March experiments showed more Cy5 signal in CsA compared to EtOH
(Fig. 19A and C). On the other hand, the February experiment reported a higher average Cy5
signal in the EtOH condition compared to the CsA 1-hour time point (Fig. 19B). Both the 2- and
3-hour time points had similar results for all assays. There was more Cy5 signal reported in the
CsA condition compared to the EtOH sample. The last time point, 4-hour, showed more Cy5
signal in CsA compared to EtOH for the March experiment (Fig. 19C). For both June and
February, there was more average CA signal in the EtOH treated sample compared to the CsA 4hour time point (Fig. 19A and C). Overall, this data indicates that there is more CA present at
specific time points.
When comparing the average CA signal for each condition, the number of virions per
sample must be considered because if one condition with more virions compared to another then
there may be an artificially increased amount of CA. The largest difference in the number of
virions when combining all the data is the 3-hour time point for the pooled data. The CsA treated
coverslips had a total of 444 virions, while the EtOH coverslips only had 170 (Fig. 18). The June
experiment viral counts per coverslip were also inconsistent, ranging from 150 to 15 virions for
the 1-hour conditions (Fig. 19A). This is because the 1-hour EtOH coverslip split into four pieces
during the experiment, and only a few fragments were saved for imaging. Also, the March
experiment 3-hour EtOH sample was lost, so that sample has data from two experiments instead
of three.

49

To ensure that there was no bias occurring from one experiment outweighing another
when pooling the data from all three experiments, the average signal was calculated by manually
averaging the mean Cy5 signal from the June, February, and March assays. The result was
similar to the average that had been produced from the pooled data and verified that no one
experiment was shifting the average (Table 4). Some subtle differences were observed, but the
average CA intensity did not change dramatically. For example, the EtOH 1 timepoint had a
manual calculation of 122.2 and a pooled calculation of 152.1 (Table 4). This difference is most
likely due to the June experiment because it only had 15 virions detected for this sample. On the
other hand, the EtOH 3 sample was nearly identical with a manual calculation of 92.94 and the
pooled average of 92.92 (Table 4). This data confirms that there is no bias present when
comparing the combined data time points.
Effect of CypA on CA Maximum and Minimum Signal. It is important to note that the
confocal microscope was functioning at the top of its detection capabilities. The maximum signal
is 251 and many virions were detected at this maximum signal, clustered at the top of each
scatterplot. Because so many virions appeared to be at this signal, the percentage of virions at
maximum Cy5 signal was calculated (Fig. 20). For most samples, there was a higher percentage
of virions at the maximum signal for CsA samples compared to EtOH samples. For the June
experiment, 1-, 2-, and 3- hour CsA samples all had over 30% of virions at the maximum signal
(Fig. 20A). The same time points for EtOH all had less than 30%. The February experiment had
more variability between samples, but at hours 2 and 3 there was more virions at the maximum
signal in CsA samples than EtOH samples (Fig. 20B). Last, the March assay reported more
virions at the maximum detection in CsA samples for all time points except 0 hours (Fig. 20C).
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This experiment had up to 72% of total virions for the CsA 3-hour time point at the maximum
signal detection.
For comparison, the percentage of virions in each sample at the minimum signal of 0 was
also calculated (Fig. 21). The general trend for all experiments was more virions at the minimum
were detected in the EtOH samples versus the CsA samples. This result was found in the June
experiments for all conditions but hour 4 (Fig. 21A). At the last hour the data switches with more
CsA samples at the minimum than EtOH. For 0- and 1-hour samples, 67% of virions were at 0
signal detection (Fig. 21B). The February assay had no discernible trend between CsA and
EtOH. Although, there were more virions at the minimum signal at the 0 hour time point
compared to the remaining samples. The March assay overall had the lowest reported percentage
of virions at the minimum Cy5 signal detection across all time points. The outlier in this
experiment was hour 1 EtOH, which had 81% (Fig. 21C). The remaining time points all had
percentages under 25% with most reporting more EtOH treated virions at 0 compared to CsA
(Fig. 21C).
Viral Fusion Analysis. Something to consider is whether or not treatment with CsA or
EtOH has an effect on viral fusion and therefore infection. To continue analysis of the in situ
assays, the percentage of fusion was calculated for each sample (Fig. 22). If the fusion is
significantly different between samples, then it is not feasible to compare uncoating between
samples. The percentage of viral fusion was calculated by dividing the number of virions that
report 0 dTomato fluorescence by the total virions counted per sample. Though fusion is
expected to vary between samples, it is not expected to increase as time increases. The BafA
control has fusion inhibited for VSVG-HIV, so any fusion in this sample is considered
background detection.
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For the June experiment, BafA exhibited 31% of background fusion, 33% for the
February experiment and 15% for the March experiment (Fig. 19A, 19B, 19C). There was a high
percentage of fusion present in the 0-hour time points for all three experiments (Fig. 22). When
comparing the percentage of fusion reported for CsA and EtOH, there was not a large enough
difference to indicate any change in fusion. Though, in each experiment, there was fusion
calculated below the BafA control fusion percentage. In the June in situ assay, both CsA and
EtOH had the highest fusion percentage at 0 hours post infection. For hours 1, 2, and 3, there was
a higher percentage of fusion present in the EtOH samples when compared to the CsA coverslips
for experiment 1 (Fig. 22). The 1-, 2-, and 3-, hour CsA samples reported 26%, 19%, and 15%
fusion respectively. EtOH fixed at 1-, 2-, and 3-, hours had a higher percentage of fusion,
showing 47%, 42%, and 41% accordingly (Fig. 22A). At the 4-hour time point, the percentage of
fusion was greater in CsA compared to EtOH. The February experiment reported similar fusion
when comparing CsA to EtOH conditions. The difference between each percentage was less that
10% for all timepoints (Fig. 22B). The March experiment did have a large difference between
the 0-hour time points, with the EtOH percentage being nearly half the CsA percentage (Fig.
22C). The 1-hour samples were similar in fusion percentages. The 2 and 4 hour time points for
the March assay both showed more fusion in the EtOH sample compared to CsA. When
considering the fusion data, all percentages were similar enough in all experiments to trust that
treatment with CsA did not affect viral function.

Effect of CypA on Human TRIM5α Restriction
In addition to facilitating uncoating, CypA may be involved in blocking TRIM5α
restriction in human cell lines (43, 62). To explore this possibility in the CHME3 cell line,
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TRIM5α was knocked down using a pool of four siRNAs. The negative controls were
knockdown with the nontarget siRNA NT4 and reaction without siRNA. The cells were treated
with pools of 4 siRNAs that targeted GAPDH as a control to analyze knockdown. The amount of
TRIM5 knockdown was quantified using qRT-PCR. To determine the effect of CypA on
TRIM5α restriction, an infectivity assay was performed on the cells in the presence and absence
of CsA. It is predicted that CypA blocks TRIM5α restriction and when CypA is inhibited,
infection will decrease. It is expected that the percent of GFP positive cells will increase when
TRIM5α is knocked down. The results from these experiments will reveal if CypA protects HIV1 from TRIM5α restriction.
Effect of CsA on HIV Infectivity. Previous data has shown that treating CHME3 cells
with CsA decreases HIV-1 infectivity (80). Similar results were found in the siRNA knockdown
experiment from May. It was found in the NT4 knockdown condition for both the raw data and
normalized data. When comparing infectivity in these cells, treatment with CsA overall
decreased infectivity when compared to cells treated with EtOH (Fig. 23A). Yet, a similar
increase was found at the dilution with the highest amount of virus in both the raw data and the
normalized data (Fig. 23A and B). The TRIM5α knockdown condition showed a decrease of
about 20% infectivity with treatment of CsA when compared to EtOH at the 1/64 (0.015625)
dilution (Fig. 23C). To compare this data further, it was normalized to the EtOH sample to
calculate a fold change. The 1/64th (0.015625) dilution in the May experiment showed a decrease
of almost 0.6 fold when TRIM5α knockdown cells were treated with CsA compared to EtOH
(Fig. 23D). There was a slight increase in the fold change at the dilution with the highest amount
of virus (0.0625 dilution), where the CsA sample reached just above the EtOH (Fig. 23D). NT4
siRNA treated cells were chosen over cells that had no siRNA treatment because the
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experimental conditions were more similar to the TRIM5α knockdown cells. Therefore, CsA
treatment did cause an expected decrease of HIV-1 infectivity in CHME3 microglial cells in both
knockdown conditions.
Effect of TRIM5α Knockdown on HIV Infectivity. To determine the effect of TRIM5α
in the presence and absence of CsA, infectivity was compared between TRIM5α knockdown and
NT4 knockdown cells. Looking at the raw data from the May experiment, the trend shows a
higher percentage of cells were infected when TRIM5α was knocked down compared to when
the restriction factor is present. This trend was present for both CsA and EtOH treated cells (Fig.
24A and C). The difference between TRIM5α and NT4 knockdown infectivity was greater in the
CsA treatment compared to the EtOH treatment. For example, the 1/32 (0.03125) dilution in the
CsA treatment had 51% infectivity in the TRIM5α knockdown cells while the NT4 knockdown
showed 35% infectivity (Fig. 24A). For comparison, the 1/32 (0.03125) dilution in the EtOH
sample had an infectivity of 60% for the TRIM5α siRNA sample compared to 49% in the NT4
pool knockdown (Fig. 24B).
To better compare the effect of TRIM5α knockdown on infection between the CsA and
EtOH treatments, the percentage of infected cells was normalized to the equivalent NT4 control
was set to 1 to calculate a fold change. For both CsA and EtOH treatments, there was a gradual
increase in the difference between the control and experimental treatment as the viral dilution
decreased from 1/16th to 1/512th. For EtOH cells, the greatest difference is at 1/256th
(0.00390625), with infectivity in the TRIM5α knockdown 2-fold higher than that in the NT4
control (Fig. 24B). The difference was even greater between the normalized NT4 and TRIM5α
reactions for the CsA sample (Fig. 24D). The largest difference was at 1/512th (0.001953125)
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dilution, the dilution with the least amount of virus, where the percent of infected cells in the
TRIM5α knockdown nearly reaches 3-fold higher than the NT4 control (Fig. 24D).
Effect of CypA on TRIM5α Restriction. Interestingly, CsA was less effective at
decreasing infectivity in cells that had a knockdown of TRIM5α. In the May experiment, when
comparing the difference of infectivity between CsA and EtOH, CsA decreased infectivity less
when TRIM5α was knocked down. The 1/32 (0.03125) dilution showed the percent of GFP
positive cells for CsA treated NT4 cells to be 35%. The EtOH infectivity for NT4 knockdown
cells was 49% (Fig. 25A). When TRIM5α was knocked down, the CsA treatment yielded an
infectivity of 51%. EtOH treatment in TRIM5α knockdown cells had an infectivity of 60% (Fig.
25A). The difference between the two knockdown conditions shows that depleting the amount of
TRIM5α present decreases the effectiveness of CsA. The same thing is seen in the normalized
data in the dilution with the least amount of virus. To normalize the data, the equivalent EtOH
reaction was set to 1 for TRIM5α and NT4 knockdowns to show the fold change in infectivity.
The TRIM5α knockdown shows a fold change of just over 0.5, whereas the NT4 knockdown
shows a change of 0.3, indicating less infectivity when the restriction factor is present (Fig. 25B).
Trends From Three Independent Experiments. For the second aim, three siRNA
knockdown experiments were conducted: March, May, and June. Both May and June had the
same viral serial dilution of 1/16th to 1/512th. The remaining experiment, March, had a serial
dilution of 1/2 to 1/64th. For all experiment to be comparable, March data from 1/16th to 1/64th is
represented in the graphs. This allows for trends to be more apparent and makes sure viral
overinfection is not skewing the results.
The March siRNA experiment showed an unexpected increase of infected cells treated
with CsA for both TRIM5α and NT4 knockdown conditions at the dilution with the highest
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amount of virus, 0.0625 dilution (Fig. 26A and C). CsA treated cells in this TRIM5α knockdown
condition exhibited a fold change increase of over 1.5 and in the NT4 knockdown condition, an
increase of around 1.2 (Fig. 26A and C). The June experiment showed similar results, but to a
less severe extent, with the TRIM5α knockdown CsA treatment showing a fold change of just
above 1 and the NT4 knockdown CsA treatment having a fold change of around 1.1 (Fig. 26B
and D). In the dilutions with a lower amount of virus, treatment with CsA caused a decrease in
HIV-1 infectivity in both March and June experiments, similar to the May experiment. At the
dilution with the least amount of virus, the CsA condition showed a fold change of near 0.8 for
both TRIM5α and NT4 knockdown conditions in the March experiment (Fig. 26A and C). The
June experiment showed a fold change of around 0.5 for both knockdown conditions at the
dilution with the lowest amount of virus as well. Therefore, CsA treatment decreased infectivity
in CHME3 microglial cells treated with lower amounts of virus in both experiments.
The effect of the TRIM5α knockdown was analyzed in the March and June experiments.
Both data sets were normalized to NT4 by setting the control to 1 to show a fold change. For the
March knockdowns, EtOH treated TRIM5α knockdown cells showed a nearly 1.3 fold change
increase compared to NT4 at the dilution with the least amount of virus (Fig. 27A). The TRIM5α
knockdown showed a larger 1.45 fold increase compared to the NT4 control when treated with
CsA (Fig. 27C). For the June experiment, the greatest difference of infectivity between the
knockdown conditions was also at the dilution with the least amount of virus, 1/512
(0.001953125). The EtOH treated knockdown cells showed a fold change of 2.3 in TRIM5α
siRNA treated cells compared to the control NT4 knockdown (Fig. 27C). The CsA condition
produced a fold change increase of 3 in TRIM5α knockdown cells (Fig. 27D). This trend of more
significant increases in infectivity of HIV-1 in microglial cells when TRIM5α is depleted was
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found for all other dilutions was found for all other dilutions for both March and June. Similar to
the May results, CsA treatment was less effective when TRIM5α expression was decreased
within the cell. At the dilution with the least amount of virus, for the March experiment,
treatment with CsA in the NT4 knockdown condition reported a fold change decrease of 0.8
compared to the same treatment in the TRIM5α knockdown that produced a fold change of 0.7
(Fig. 28A). In the June experiment, the 1/64 (0.015625) dilution showed a fold change decrease
of 0.6 in the CsA treated NT4 condition (Fig. 28B). At the same dilution, the CsA treated
TRIM5α knockdown produced a fold change of 0.9 (Fig. 28B). To see if this is an ongoing trend,
the fold change for each dilution was averaged for all experiments. The greatest fold change
difference was present in the dilution with the highest amount of virus, where the average for
CsA treated NT4 knockdown cells was around 1.1 and the average for CsA treated TRIM5α
knockdown cells was around 1.3 (Fig. 29). For the other dilutions, there was a slight increase in
the fold change between CsA treated NT4 and TRIM5α knockdown conditions. This data
indicates that CsA does not function as efficiently when the restriction factor expression is
decreased.
Knockdown Quantification. The primer efficiency was not able to be calculated for the
TRIM5α, so the amount of TRIM5α knockdown remains to be defined (see Appendix B).
Fortunately, the GAPDH knockdown control was able to be quantified for the June experiment.
For this quantification, ten RNA samples isolated from various knockdown conditions and
controls were run in triplicate: TRIM5α knockdown with and without reverse transcriptase,
GAPDH knockdown with and without reverse transcriptase, NT4 knockdown with and without
reverse transcriptase, no siRNA control with and without reverse transcriptase, and water with
and without reverse transcriptase. The Ct values from qRT-PCR were averaged for the triplicate
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runs (Table 5). The -RT reactions and water samples had average Ct values ranging from 29-33,
indicating no contamination (Table 5). For the no siRNA, NT4, and TRIM5α samples with
reverse transcriptase, average Ct values ranged from 13-15 (Table 5). The GAPDH knockdown
average Ct value was 18.88, a 10-fold difference compared to the other samples (Table 5). The
average for the GAPDH knockdown was calculated using values from Ct1 and Ct2 because the
number from Ct3 was a much later cycle than expected. Since the value for Ct3 for the GAPDH
knockdown was 28.62, it is most likely that there was no RNA added to the sample. The Ct3
result for the +RT GAPDH knockdown was more similar to the -RT reactions for the GAPDH
sample, with numbers ranging from 28.71 to 29.07. Though the TRIM5α knockdown was not
able to be analyzed, the GAPDH qPCR results indicate a knockdown of expression.

TABLE 4 Average Cy5 Signal
Sample
June

Feb

March

Pooled

Average of June,
February, March

CsA 0

45.05

91.28

91.75

80.62

76.02

EtOH 0

39.79

73.50

33.12

59.61

48.8

CsA 1

138.3

131.9

191.4

150.5

153.8

EtOH 1

49.87

147.4

169.2

152.1

122.2

CsA 2

134.9

179.7

219.7

174.5

178.1

EtOH 2

106.6

164.7

190.3

164.7

153.86

CsA 3

162.3

120.9

192.0

157.7

158.4

EtOH 3

91.72

94.17

-

92.92

92.94

CsA 4

89.52

151.7

210.5

137.3

150.57

EtOH 4

149.9

181.6

175.9

166.7

169.13

BafA

171.5

130. 9

176.9

160.0

159.76
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TABLE 5 GAPDH Knockdown qRT-PCR Results.
Sample
Ct 1
Ct 2

Ct 3

Average

TRIM5α +RT

15.55

15.40

16.16

15.70

TRIM5α -RT

29.55

29.68

29.97

29.73

GAPDH +RT

18.99

18.76

28.62*

18.88

GAPDH -RT

29.02

28.71

28.89

28.87

NT4 +RT

13.24

14.69

15.08

14.34

NT4 -RT

30.07

30.37

30.22

30.22

No siRNA +RT

12.93

13.26

13.66

13.28

No siRNA -RT

29.35

29.20

29.33

29.29

Water +RT

29.64

30.16

29.69

29.83

Water -RT

31.85

32.98

34.81

33.21

*Not included in the average

FIG 15 Dual Labeled Virus Schematic. The membrane of each virion is labeled with dTomato,
and the viral core has been labeled with GFP. Unfused virus displays dTomato labeling. Fused
and coated virus are GFP and Cy5 positive. Cy5 fluorescence is provided by primary and
secondary antibody staining. Fused and uncoated virus are only GFP positive (82).
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FIG 16 Graph of Virus Validation. Membrane fluorescence and capsid staining was analyzed
for each stock of dual labeled virus.
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FIG 17 Representative In Situ Assay Image. The image shows the confocal microscopy of
CHME3 cells infected with dual labeled virus and stained for CA. (A) GFP-Vpr labeling
shows the location of fused and uncoated virions. Virions appear in the image as green pixels.
(B) dTomato labeled virions show unfused virus. This is a control to ensure that only CA from
fused virus is included in the uncoating analysis. (C) Cy5 antibody staining portrays where CA
for each virion is located. (D) Overlay of all labeling and staining.
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FIG 18 Scatterplot of Pooled In Situ Assay Data From Three Independent Experiments. Each
dot represents one virion in each condition. The CA signal detection is represented on the Y
axis and is Cy5 signal. The maximum signal is 251. The red bar is the average signal for each
condition.
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FIG 19 In Situ Uncoating Assay Maximum Cy5 Fluorescence. Continued with legend on the
next page.
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FIG 19 Continued In Situ Uncoating Assay Maximum Cy5 Fluorescence. Each scatterplot
represents one assay. Cy5 signal intensity is represented as a scatterplot to show presence of
capsid in each sample. The maximum threshold for the scatterplot is 251 CA signal. The red
bar is the average signal for each sample. (A) June experiment. (B) February experiment. (C)
March experiment.
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FIG 20 Percent Maximum Cy5 Signal. Continued with legend on the next page.
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FIG 20 Continued Percent Maximum Cy5 Signal. Each graph represents one experiment and
shows the percentage of virions reporting Cy5 signal at the maximum detection of 251. (A)
June experiment. (B) February experiment. (C) March experiment.
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FIG 21 Percent Minimum Cy5 Signal. Continued with legend on the next page.
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FIG 21 Continued Percent Minimum Cy5 Signal. Each graph represents one experiment and
shows the percentage of virions reporting Cy5 signal at the minimum detection of 0. (A) June
experiment. (B) February experiment. (C) March experiment.
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FIG 22 In Situ Assay Percent Viral Fusion. Continued with legend on the next page.
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FIG 22 Continued In Situ Assay Percent Viral Fusion. Graph of percentage of virions fused at
each time point for all conditions. BafA is the fusion inhibitor control. (A) June experiment.
(B) February experiment. (C) March experiment.
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FIG 23 Effect of CsA Treatment in TRIM5α and NT4 Knockdown May Experiment
Continued with legend on the next page.
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FIG 23 Continued Effect of CsA Treatment in TRIM5α and NT4 Knockdown May
Experiment. (A) Raw data of NT4 knockdown cells treated with CsA or EtOH. Shows the
percentage of infected cells. (B) Fold change of NT4 knockdown data normalized to EtOH.
(C) Raw data of TRIM5α knockdown cells treated with CsA or EtOH. Shows the percentage
of infected cells. (D) Fold change of TRIM5α knockdown data normalized to EtOH.
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FIG 24 Effect of TRIM5α in EtOH and CsA Treated Cells May Experiment. Continued with
legend on the next page.
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FIG 24 Continued Effect of TRIM5α in EtOH and CsA Treated Cells May Experiment. (A)
Raw data of TRIM5α knockdown cells and NT4 knockdown cells treated with EtOH. Shows
the percentage of infected cells. (B) Fold change of TRIM5α knockdown and NT4 knockdown
cells treated with EtOH normalized to NT4. (C) Raw data of TRIM5α knockdown cells and
NT4 knockdown cells treated with CsA. Shows the percentage of infected cells for each
condition. (D) Fold change of TRIM5α knockdown cells and NT4 knockdown cells treated
with CsA normalized to NT4.
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FIG 25 Effect of CypA in TRIM5α and NT4 KD Cells, May Experiment. (A) Raw data of
TRIM5α and NT4 knockdown cells treated with CsA or EtOH. Percentage of infected cells is
shown. (B) Data from figure (A) normalized to EtOH to show the fold change in infection.
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FIG 26 Effect of CsA Treatment on TRIM5α and NT4 Knockdown Cells in March and June
Experiments. Continued with legend on the next page.
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FIG 26 Continued Effect of CsA Treatment on TRIM5α and NT4 Knockdown Cells in March
and June Experiments. (A) March experiment, fold change of NT4 knockdown data in CsA
and EtOH treated cells normalized to EtOH. (B) June experiment, fold change of NT4
knockdown data in CsA and EtOH treated cells normalized to EtOH. (C) March experiment,
fold change of TRIM5α knockdown data in CsA and EtOH treated cells normalized to EtOH.
(D) June experiment, fold change of TRIM5α knockdown data in CsA and EtOH treated cells
normalized to EtOH.
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FIG 27 Effect of TRIM5α Knockdown in CsA or EtOH treated cells, March and June
Experiments. Continued with legend on the next page.
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FIG 27 Continued Effect of TRIM5α Knockdown in CsA or EtOH treated cells, March and
June Experiments. (A) March experiment, fold change of TRIM5α knockdown and NT4
knockdown cells treated with EtOH, normalized to NT4 to show the fold change in infection.
(B) June experiment, fold change of TRIM5α knockdown and NT4 knockdown cells treated
with EtOH, normalized to NT4 to show the fold change in infection. (C) March experiment,
fold change of TRIM5α knockdown and NT4 knockdown cells treated with CsA, normalized
to NT4 to show the fold change in infection. (D) June experiment, fold change of TRIM5α
knockdown and NT4 knockdown cells treated with CsA, normalized to NT4 to show the fold
change in infection.
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FIG 28 Effect of CsA in TRIM5α and NT4 Knockdown Cells, March and June Experiments.
(A) March data normalized to EtOH to show the fold change in infection in NT4 and TRIM5α
knockdown cells treated with CsA or EtOH. (B) June data normalized to EtOH to show the
fold change in infection in NT4 and TRIM5α knockdown cells treated with CsA or EtOH.
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FIG 29 Average Fold Change of the Effect of CsA for Pooled Data. The bar graph shows the
average fold change of infection for all experiments. The purple bars are cells treated with
EtOH and the blue bars are cells treated with CsA. The dilutions 1/16 to 1/64 are averaged
from 3 experiments. Dilutions 1/128 to 1/512 are averaged from 2 experiments. Error bars
denote standard error among 3 experiments for dilutions 1/16 to 1/64 and 2 experiments for
dilutions 1/128 to 1/512.
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DISCUSSION

Blocking CypA-CA Interactions Inhibits HIV-1 Capsid Uncoating
HIV-1 uncoating is affected based on the presence and absence of CypA binding. Use of
the in situ uncoating assay demonstrated that removing CypA-CA interactions by treatment with
CsA increased the amount of CA present compared to treatment of EtOH (Fig. 18). This
indicates a change in the amount of HIV-1 capsid uncoating.
When comparing the Cy5 antibody staining for the virus on glass assays completed with
dual labeled virus, there was an unexpectedly low amount of fluorescence detected for the
second round of stocks produced (Fig. 16). Stocks A, B, and C all had less than 20% Cy5 signal
detected. This is almost certainly because of improper CA antibody staining and not due to a lack
of CA. The focus of the virus on glass assay is the dTomato labeling to ensure that the cells
producing the virus were successfully transfected with the four plasmids used. For all stocks
made, there was 75% or more dTomato staining, indicating that all stocks had the proper
fluorescent tags because at least 75% of virus labeled with GFP also had the proper dTomato
membrane label.
The data produced from the in situ uncoating assay experiments indicates that CypA is
assisting with HIV-1 uncoating. The average amount of Cy5 signal for each condition is
corelated with the amount of uncoating present. The less CA detected in each sample, the more
uncoating was present at that time and condition. When pooling the data, there is more uncoating
present in the EtOH treatments where CypA is able to bind to CA compared to the CsA
treatments for 2-, and 3- hours post infection (Fig. 18 and Table 5). The average Cy5 signal for
the pooled 1-hour data is almost the same, 150.5 and 152.1 for CsA and EtOH treatments
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respectively. At the 4-hour time point, the pooled data and independent experiments, showed an
unexpected result of more uncoating when the interaction between CypA and CA is blocked.
The microscope used had a maximum signal detection of 251 and a minimum signal
detection of 0. When the percent of virions at the maximum detection was calculated, it was
found that overall, a higher percentage of timepoints treated with CsA were at the maximum
when compared to EtOH. This may mean that the average for the CsA samples may be higher
than currently calculated. If up to 72% of virions are at the top signal, it is possible that the
amount of CA signal far exceeds the detection limit of the microscope. On the other hand, there
was overall more EtOH samples at the minimum signal detection of 0. This means that there was
no CA detected for the virion analyzed. At the most, up to nearly 80% of virions counted in the
EtOH 0-hour sample in the March experiment were at 0. Therefore, there may be even more CA
present in the CsA samples and less in the EtOH samples which further supports the hypothesis
that CypA-CA interactions assist with uncoating.
For the average amount of Cy5 signal, there was a consistent switch between CsA and
EtOH between 3- and 4- hours post infection for all three experiments. All experiments had more
Cy5 fluorescence for CsA compared to EtOH at the 3-hour time points and this swapped at 4hours for both June and February experiments. The 3-hour EtOH coverslip for the March
experiment data was lost, so it is unknown whether or not this change occurred in this
experiment as well. The change in the amount of CA present in the 4-hour samples may be due
to a population of virus starting to fuse with the cell membrane. It is also possible that CsA
treatment was depleted by 4-hours post infection. The warm media that the cells were treated
with after spinoculation did not contain CsA or EtOH. The half-life of CsA for this experiment is
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not known, so it may be that the drug is no longer associated with CypA at this time point. This
could change the CA fluorescence detected between 3- and 4- hours post infection.
When comparing the average CA signal for each condition, the number of virions
counted must be taken into consideration. Though analysis was still conducted, it may not be
reasonable to compare results for 1-hour samples in the June experiment because there were only
15 virions detected for EtOH and 163 virions detected for CsA (Fig. 18). Since the coverslip was
broken multiple times, the surface area for imaging was greatly decreased. There was less Cy5
fluorescence detected for EtOH compared to CsA for these samples, but since the EtOH sample
contained less than 1% of the virus detected for CsA, the results are not reliable.
For all in situ assay experiments, there were coverslips that reported fusion lower than the
BafA control. The BafA sample was used to show background fusion detection when dual
labeled virus fusion is inhibited. Due to the nature of the assay, it is entirely possible that
dTomato labeling was lost during experimentation. During the primary antibody staining, each
coverslip is treated with a permeabilization solution that perforates the cell membrane to allow
the antibody to enter the cells. This solution also permeates the viral membrane and causes loss
of dTomato labeling. It is also possible that the detected virus never contained the dTomato
label. When producing dual labeled virus, 293T cells are transfected with four different plasmids.
It is unrealistic that the cells would take up all four plasmids and that every virion produced
would have both GFP and dTomato labeling. This is the reason for the virus on glass assay, to
ensure the virus used has a high percentage of both GFP and dTomato labeling. Therefore, some
experimental samples may have less fusion detected compared to the BafA control.
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Previous Research on Interactions Between CypA and CA
Effecting uncoating is not the only role of CypA in the replication cycle of HIV-1.
Previous research has found CypA to be involved in reverse transcription and nuclear import in
microglial cells (80). Treatment with CsA resulted in a decrease of reverse transcription. There
was a greater than 20% difference in reverse transcription completion between samples treated
with CsA compared to EtOH. It was concluded that CypA-CA interactions assist with reverse
transcription (80). To further analyze the role of CypA in HIV-1 early replication, nuclear import
was investigated by evaluating the quantification of 2-LTR circles as an indicator of import. It
was found that treatment with CsA produced a decrease of nuclear import compared to samples
treated with EtOH. Though the decrease in nuclear import may be due to downstream effects
caused by a decrease in reverse transcription, it was concluded that blocking CypA-CA
interactions also decreased nuclear import (80). Finally, early investigations for the role of
CypA-CA interactions in uncoating were defined. Though the differences between CsA and
EtOH treated samples were not as distinct, the 1-hour time point did show more CA signal when
CypA-CA interactions were inhibited (80). The initial experiments did not include a 3-hour time
point, so the time point with the largest difference from this experiment cannot be compared.
Investigating the role of CypA in capsid uncoating in microglial cells has produced
similar results to reverse transcription and nuclear import. Blocking the interaction between
CypA and CA decreased uncoating. Since the exact model of uncoating has yet to be determined,
it cannot be stated whether uncoating occurs simultaneously, before, or after reverse transcription
(13). It may be possible that treatment with CsA inhibits uncoating and therefore decreases
reverse transcription and nuclear import. If uncoating does not happen at the proper part of
replication, this could inhibit reverse transcription and a decrease in viral cDNA would therefore
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decrease nuclear import. Altogether, there is a decrease in early replication steps when CypA
cannot bind to CA and whether this effects one specific step or multiple remains to be
determined.

Models of Uncoating
There are currently three proposed models of uncoating: biphasic, nuclear pore complex
(NPC), and nuclear uncoating. Though the data generated does not prove one model over
another, it may support NPC and nuclear uncoating. The greatest difference in uncoating
between CsA and EtOH treatments was between 2- and 3-hours post infection. Therefore,
uncoating may be occurring more frequently at these time points compared to others because the
effect of CsA would be greatest when the capsid is uncoating. It is probable that the capsid is
closer to the nucleus than the point of fusion after multiple hours post infection, so the data does
not support biphasic uncoating. In consideration of the data, it is likely that the capsid is
uncoating at the nuclear pore, or once completely within the nucleus.

TRIM5α Restriction Is Blocked by CypA in Microglial Cells.
By knocking down TRIM5α in CHME3 microglial cells, HIV-1 infectivity increased
compared to the NT4 knockdown control. In previous experiments, human TRIM5α restriction
has been found to work in human cell lines when CypA cannot bind to the capsid (43, 62). It is
believed that CypA binds to the capsid and blocks TRIM5α restriction, and a similar conclusion
can be drawn from these siRNA knockdown experiments.
All experiments conducted produced similar trends when cells were treated with CsA and
EtOH. For all dilutions except where the amount of virus was the highest, treatment with CsA
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decreased infectivity (Fig. 23 and 26). This was an expected result, as it has been found in
previous work with microglial cells (80). When analyzing the fold change, there was a greater
difference between CsA and EtOH in the dilutions that contained less virus. In all experiments,
an increase of infection was seen at the 1/16th dilution, the dilution with the highest amount of
virus, despite treatment with CsA. This is most likely due to too much virus. Treating the cells
with high amounts of HIV can create false positives by overwhelming the cells. Too much virus
can cause cells to become infected more than once and surpass the natural restriction of the cells
by saturating restriction factors. Comparing CsA versus EtOH treatment in the other dilutions
ensures that CsA still decreases infectivity in CHME3 cells at lower dilutions. Knocking down
TRIM5α did not cause any unexpected changes in infectivity.
To see what effect TRIM5α knockdown had on infectivity and if this changed with the
presence and absence of CsA, the data was normalized to NT4 to show the fold change in
infectivity (Fig. 24 and 27). Overall data from all experiments shows that knocking down
TRIM5α increased HIV-1 infectivity. This indicates that TRIM5α is able to restrict HIV
infection in human microglial cells. Further, treatment with CsA caused an even greater
difference, showing a change of 3-fold higher in the June experiment (Fig. 27D). TRIM5α is able
to restrict HIV-1 infection in this cell line when cells are treated with EtOH or CsA. An increase
of this effect on infectivity was found in all experiments when cells were treated with CsA. This
indicates that CypA is blocking TRIM5α restriction and that blocking CypA-CA interactions
allows for more restriction.
An interesting conclusion can be drawn from the effect of CsA in TRIM5α and NT4
knockdown results. The ability of CsA treatment to decrease infectivity in CHME3 microglial
cells may be, in part, due to TRIM5α restriction. Treatment with CsA blocks the interaction
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between CypA and CA, therefore allowing for TRIM5α restriction. By removing CypA,
TRIM5α is able to bind to the capsid to disrupt proper uncoating kinetics within this human cell
line. When analyzing the effect of CsA in TRIM5α and NT4 knockdown cells, there was a
greater decrease of infectivity in the NT4 control. By decreasing TRIM5α expression in the cell,
the effect of CsA was consistently decreased. This further supports the hypothesis that CypA is
blocking TRIM5α restriction within human microglial cells.
Two previous experiments have detailed the relationship between CypA and TRIM5α in
macrophages and lymphocytes (43, 62). Both experiments found that blocking CypA binding to
CA decreases infectivity. In macrophages, knocking down TRIM5α rescued infectivity to just
below the control of 100% infection (43). In lymphocytes, decreasing TRIM5α expression with
CRISPR also rescued infectivity to the same as the control (62). In both cell types, the data
indicates that blocking CypA-CA interactions allows for TRIM5α restriction. This restriction
does not occur when CypA proteins are bound to the capsid. Similar results were produced when
investigating the relationship between CypA and TRIM5α in microglial cells. With treatment of
CsA, infectivity decreased compared to the control (Fig. 23 and 26). Unlike the other
experiments, when TRIM5α was knocked down, infectivity was not fully rescued. Yet, there was
a lesser decrease of infectivity, indicating that removing the restriction factor does increase
infectivity. It can be concluded that there is a similar link between CypA and TRIM5α in
microglial cells as there is in macrophages and lymphocytes. Since infectivity was not entirely
rescued when TRIM5α was knocked down, CypA may be involved in other roles in HIV-1
replication.

88

Future Directions
There are follow up experiments that should be completed in order to learn more about
the role of CypA in HIV-1 capsid uncoating. To begin, the in situ assay should be imaged on a
microscope with a higher signal limit. Increasing the limit would determine the true average CA
detection for each condition and avoid virions clustering at the top of the detection limit. From
the results produced here, it can be expected that the averages for CsA treatments would be
greater than what was found. It is also possible that there would be an even greater difference
between CsA and EtOH because of this. Another experiment would be to use other methods to
stop CypA from binding to CA. This ensures that the change in uncoating is due to CypA and
not off target effects of CsA. An example would be to use the capsid mutant P90A. This capsid
has a mutation in the CypA binding loop and blocks CypA association with CA. Using wildtype
capsid and P90A in place of EtOH and CsA would determine whether or not CypA effects
uncoating and if there are other factors involved. The expected results would be a decrease in
capsid uncoating when CypA is not able to bind, similar to treatment with CsA. Last, it would be
interesting to test the in situ uncoating assay in other cell types. Microglial cells and astrocytes
make up the majority of the viral reservoir in the brain (86). Investigating the relationship
between CypA and uncoating in astrocytes may reveal more information about HIV-1 replication
in neural cell lines. I would expect the two cell lines to react to CsA treatment similarly because
they are both a part of the immune system for the CNS.
To further investigate the interplay between CypA and TRIM5α, a knockdown
experiment to decrease CypA expression would be useful. Knocking down CypA to see if the
effect is similar to CsA treatment would ensure that the reason TRIM5α cannot restrict infection
in human cell lines is due to CypA. Knocking down CypA in microglial cells could be
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accomplished similar to the TRIM5α knockdown, with a siRNA to target CypA. If CypA is
blocking TRIM5α, then the knockdown results should be similar to treatment with CsA.
Therefore, it would be expected that decreasing CypA expression would decrease HIV-1
infectivity.
Another continuing experiment would be to calculate the primer efficiency for the
TRIM5α primers. This would reveal what degree TRIM5α was knocked down. Knowing how
much TRIM5α expression decreased in the cell can explain any differences between siRNA
experiments. Low TRIM5α knockdown may also be why infectivity was not fully rescued when
the restriction factor was knocked down. Since there was a difference in infectivity between
experiments, it can be speculated that there is a difference in the amount of knockdown achieved
for each experiment.
Since interplay between TRIM5α and CypA has been determined in microglial cells, I
believe the next step is to investigate the protein death domain-associated protein 6 (Daxx). This
protein is a chaperone protein involved in many mechanisms, including apoptosis and
carcinogenesis. In a recent study, Daxx was found to form a complex with the HIV-1 capsid
through interaction with CypA (87). Using immunoprecipitation, HIV-1 capsid revealed a
complex formed by Daxx, CypA, TRIM5α, TRIM34, and TNPO3 (87). It is possible that Daxx
is an important part of HIV-1 early replication, specifically uncoating. The interplay between
Daxx and the other proteins was analyzed in HEK293T cells. Investigating this relationship in
microglial cells may reveal more about the role of CypA in early replication. To research Daxx
in microglial cells, the expression could be decreased using siRNA. Then, an in situ uncoating
assay could be conducted on the knockdown cell lines. If Daxx is involved with CypA and
uncoating, then decreasing expression should decrease the amount of uncoating. Using the same

90

knockdown cells, TRIM5α restriction could also be investigated. By conducting an infectivity
assay using HIV-GFP, infectivity could be analyzed between Daxx, TRIM5α, and control
knockdown conditions. If Daxx inhibits restriction, then knocking it down would decrease
infectivity. Researching Daxx may be the key to characterizing the role of CypA in HIV-1
replication.

Conclusion
Overall, I found that CypA interacting with the HIV-1 capsid plays two roles in HIV
replication: assisting with proper uncoating kinetics and blocking TRIM5α restriction. Removing
the interaction between CypA-CA decreased capsid uncoating. Similarly, treatment with CsA
allowed for TRIM5α capsid restriction and ultimately decreased infectivity of HIV-1. It is
possible that the interaction between CyA and CA plays more than one role in HIV-1 infection
and replication, as blocking the interaction has been found to effect uncoating, reverse
transcription, and nuclear import (80). This research has characterized the role of CypA in the
uncoating step of replication and shown that TRIM5α restriction occurs within microglial cells.
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Appendix B: TRIM5α Primer Efficiency
Primer efficiency calculation is an important part of knockdown quantification because it
indicates the performance of the primers. High performance primers have an efficiency around
90% to 110%. This number indicates how much amplification is occurring in each qPCR cycle
and is used to determine the amount of RNA expression has been knocked down in a sample
using the Pfaffl method.
To begin the process of calculating TRIM5α primer efficiency, total RNA was isolated
from CHME3 microglial cells. Next, a reverse transcription reaction was completed with the
RNA to make complimentary DNA (cDNA). To start testing the primers, 3 sets of forward and
reverse primers were selected: A, C and E. A PCR reaction was conducted with each primer set
to amplify the cDNA. To visualize the PCR results, the products were run on a 3% gel for gel
electrophoresis (Fig. A1). Primers A and C were selected for further experiments because the
bands produced indicated a large amount of sample. The brighter bands indicate that the primers
are amplifying the target. Primer set E did show some amplification, but there were also bands in
the -RT and water controls.
Next, primer sets A and C were used to amplify the cDNA again, this time with the goal
of cloning the PCR product into a plasmid. The PCR products from primers A and C underwent
a PCR cleanup to purify the DNA, then a ligation reaction to insert the PCR product into the
pGem-Teasy plasmid. HB101 competent E. coli was transfected with the ligation reactions and
plated onto LB-Amp plates. Bacteria grew on the plates but resembled a lawn more than
individual colonies for both plasmid sets. Despite this, five colonies were picked from each plate
and grown in cultures, for a total of ten samples. Each culture underwent miniprep purification,
to isolate the plasmid from the samples. To check if the insert was in the isolated plasmids, an
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EcoR1 restriction digest was completed using the miniprep DNA. To see the results of the digest,
samples were run out on a gel (Fig. A2). For all ten samples, there was no insert present in any of
the plasmids. The cleaned up PCR reactions for A and C primers were run on PCR to check for
insert and it was not present in either sample (Fig. A3).
To begin the process again, new PCR products were produced using the A and C primer
sets. The products went through a PCR clean up reaction to purify the DNA with a new PCR
cleanup kit. Using the purified products from A and C primers, a ligation reaction was done with
the pGem-Teasy plasmid again. Competent HB101 cells were transfected with the ligations. The
transfected E. coli was grown up on new LB-Amp plates and single colonies were grown for
each sample. For both A and C transfections, six colonies were selected and gown in individual
cultures. After growing overnight, the twelve total samples underwent miniprep purification to
isolate the cloned plasmids.
The isolated plasmids went through an EcoR1 restriction digest to locate the insert within
the cloned plasmids. The samples were run on a gel to visualize the results and no insert was
found in the twelve samples (Fig. A4). In an attempt to find insert, the purified miniprep DNA
was run through PCR using A and C primers. After running the PCR products out on a gel, faint
bands were seen and miniprep samples A1, A3, C1, and C3 were selected moving forward (Fig.
A5). The HB101 cultures that produced the selected miniprep samples were streaked out onto
LB-Amp plates to produce more colonies. From the A3 plate, four colonies were selected and
grown in cultures. As before, the cultures were purified using a miniprep kit.
To begin developing the qPCR, the total RNA was run with primer sets A and C. The
conditions ran were samples with reverse transcriptase, without reverse transcriptase, and a no
template control for each primer set (Table A1). Moving forward, primer set A was selected
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because there was amplification at 18 cycles. C was not selected because the miniprep PCR
showed two bands, one of which may be off target amplification. Next, qPCR was conducted
with a serial dilution using the A3 miniprep DNA. The serial dilution was from 107 to 101 and a
water control. The results from this qPCR had mostly background amplification, with the lowest
cycle number being 31.62 from the no template control (Table A2). All Ct values for
experimental samples exceeded that of the negative control (Table A2). The entire 107 triplicate
set reported a Ct value of 0, showing that there may have been no target in the sample at all.
Since only background was produced, the A3 stock, 107 sample, and water were run on PCR
using primer set A to look for the insert. The PCR products were run out on a gel and there was
insert in the A3 stock, but not in the 107 sample.
Moving forward, the A3 stock was used to make a new dilution series and the miniprep
stock was used as the 107 sample. This new dilution series was also 107 to 101. The results from
the qPCR run with the new dilution series had some amplification in the 106, 105, and 104
samples. The amplification was low, with Ct values of 24, 27, and 31 for 106, 105, and 104
respectively, but it was better than the previous qPCR results (Table 3). For the next qPCR,
dilutions were added in between the samples with amplification to make 105.5 and 104.5. This
dilution series was run on qPCR four separate times, but an acceptable primer efficiency curve
was not able to be calculated (Fig. A6). To accept the primer efficiency, the line of the graph
must fit the positive trend line to produce an R2 value of 0.99 or above. This indicates that the
primers are effectively replicating the target and doubling the target each cycle. If the R2 is below
0.99, then the primers are not acceptable (Fig. A6).
In an attempt to try again, another culture of the A3 cloned plasmid was purified, this
time with a maxiprep kit. But when the sample was digested with EcoR1, no insert was present
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once again (Fig. A7). The same result was produced when the maxiprep A3 DNA was amplified
through PCR and run out on a gel using the A primers (Fig. A8). In a final effort to calculate
primer efficiency, qPCR was conducted on a serial dilution of cDNA. The total RNA isolated
from CHME3 microglial cells was processed through a reverse transcription reaction to produce
total cDNA. The cDNA was amplified using PCR and the A primer set. Some PCR product was
observed, so a serial dilution was set up for qPCR (Fig. A9). The cDNA dilution ranged from 105
to 101. The results from this final qPCR using primer set A showed mostly background once
again. The samples were run in triplicate, and the amplification was different for each trio of Ct
values (Table A4). For example, the 103 dilution reported amplification at cycles 42, 31, and 28
(Table A4). These numbers were essentially the same as the water and negative controls, which
had Ct values ranging from 27 to 41 (Table A4). Ultimately, the primer efficiency for the
TRIM5α primer set was not able to be calculated.

TABLE A1 qRT-PCR Ct values
Samples
Ct values
A +RT

18.62

A -RT

32.09

A nontarget control

38.05

Blank

N/A

Blank

N/A

C + RT

16.82

C -RT

30.93

C nontarget control

32.44

105

TABLE A2 qPCR for 107 to 101.
Samples
Ct values
107

0

107

0

107

0

106

41.8

106

33.37

106

41.27

105

0

105

33.7

105

34.41

104

35.19

104

32.48

104

36.12

103

0

103

0

103

35.85

102

37.27

102

34.56

102

35.26

101

34.33

101

34.02

101

35.21

NTC

0

NTC

31.62

NTC

33.47

106

TABLE A3 qPCR A3 Serial Dilution
Samples
Ct values
107

0

107

0

107

0

106

24.74

106

24.71

106

24.69

105

27.9

105

27.91

105

28.06

104

31.42

104

31.62

104

31.74

103

34.08

103

35.02

103

34.96

102

35.01

102

36

102

36.04

101

39.28

101

35.68

101

34.29

NTC

34.86

NTC

34.53

NTC

33.99

107

TABLE A4 qPCR on cDNA Serial Dilution
Samples
Ct values
106

23.70

106

28.20

106

24.38

105

29.69

105

31.35

105

33.11

104

38.12

104

31.33

104

30.73

103

42.19

103

31.54

103

28.13

102

37.40

102

35.86

102

28.18

101

35.56

101

31.18

101

28.50

-RT

35.80

-RT

41.59

-RT

28.39

H2 O

38.66

H2 O

30.94

H2 O

27.98

108

FIG A1 Testing Primer Amplification. PCR results on gel electrophoresis. Three primer sets, A,
C, and E were tested on total RNA. Plus, reactions contained reverse transcriptase, minus did not
have reverse transcriptase and H2O samples had no template. Cropped to show relevant lanes.
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FIG A2 Miniprep Samples EcoR1 Digest. Restriction digest results on gel electrophoresis. Ten
total samples of purified DNA for primer sets A and C. Gel has been cropped to only show lanes
with samples.
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FIG A3 Insert for Cloning into pGem-Teasy Plasmid with A and C Primers. The plus indicates
the reverse transcription reaction. The gel has been cropped to show relevant lanes.
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FIG A4 Restriction Digest for A 1-6 and C 1-6 Miniprep. EcoR1 restriction digest reaction for
twelve different miniprep samples. A indicates the A primer set and C is the C primer set. Gel
has been cropped.
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FIG A5 PCR Reaction on Minipreps. PCR with miniprep DNA for A 1-6 and C 1-6.

FIG A6 Attempted Primer Efficiency Curve. This curve was produced from the qPCR with the
dilution series 105, 104.5, 104, 103.5, 103.
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FIG A7 EcoR1 Restriction Digest. Digest results for maxiprep samples TRIM, SPTBN1, and
GAPDH.

FIG A8 PCR on Maxiprep. Maxiprep on cloned A3 sample. Remaining lanes are PCR for
maxiprep clones for SPTBN1 and GAPDH. Gel is cropped.
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FIG A9 Reverse Transcription Reaction on Total RNA. +RT indicates presence of reverse
transcriptase. -RT had no reverse transcriptase.
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